_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,direction,b1,b2,direction_gold,e1,e2,relation,relex_relcos,sent_id,sentence,term1,term2,twrex
502934677,7/14/2014 17:02:41,,1322964497,7/14/2014 17:02:32,clixsense,0.8194,27793793,GBR,C5,Chester,151.230.27.155,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,108,71,,137,90,treats,0.995893206467704,907332-FS1-2,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN,RO-may_prevent
502934677,7/14/2014 17:08:31,,1322967285,7/14/2014 17:08:26,neodev,0.6389,25224036,CAN,ON,Sudbury,67.204.218.187,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,108,71,,137,90,treats,0.995893206467704,907332-FS1-2,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN,RO-may_prevent
502934677,7/14/2014 17:23:48,,1322975119,7/14/2014 17:23:33,instagc,0.8125,18960682,GBR,"","",86.29.147.112,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,108,71,,137,90,treats,0.995893206467704,907332-FS1-2,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN,RO-may_prevent
502934677,7/14/2014 18:02:16,,1323002249,7/14/2014 18:01:58,prodege,0.4264,12944140,GBR,I4,Mitcham,92.21.55.247,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,108,71,,137,90,treats,0.995893206467704,907332-FS1-2,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN,RO-may_prevent
502934677,7/14/2014 18:09:10,,1323006776,7/14/2014 18:08:22,prodege,0.5502,7899370,USA,MI,Bay City,71.13.81.162,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,108,71,,137,90,treats,0.995893206467704,907332-FS1-2,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN,RO-may_prevent
502934677,7/14/2014 18:32:49,,1323017092,7/14/2014 18:32:30,clixsense,0.7071,16827630,GBR,A7,Birmingham,86.146.169.103,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,108,71,,137,90,treats,0.995893206467704,907332-FS1-2,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN,RO-may_prevent
502934677,7/14/2014 18:47:10,,1323023816,7/14/2014 18:47:04,clixsense,0.4121,19162475,GBR,M3,Frome,82.33.126.30,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,108,71,,137,90,treats,0.995893206467704,907332-FS1-2,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN,RO-may_prevent
502934678,7/14/2014 17:51:19,,1322997292,7/14/2014 17:50:59,clixsense,0.6389,19803139,NLD,06,Veldhoven,212.61.84.196,GASTRO INTESTINAL POLYPS causes POLYPOID LESION,106,33,,120,57,causes,0.577350269189626,901529-FS1-4,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS,RO-disease_has_finding
502934678,7/14/2014 18:14:37,,1323009331,7/14/2014 18:13:55,instagc,0.4639,28519532,USA,IA,Honey Creek,12.73.110.131,no_relation,106,33,,120,57,causes,0.577350269189626,901529-FS1-4,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS,RO-disease_has_finding
502934678,7/14/2014 18:56:37,,1323029095,7/14/2014 18:55:57,instagc,0.5877,19686223,CAN,BC,Surrey,184.65.16.6,no_relation,106,33,,120,57,causes,0.577350269189626,901529-FS1-4,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS,RO-disease_has_finding
502934678,7/14/2014 19:30:23,,1323049718,7/14/2014 19:29:59,neodev,0.6472,14861092,GBR,I2,Manchester,90.194.137.76,GASTRO INTESTINAL POLYPS causes POLYPOID LESION,106,33,,120,57,causes,0.577350269189626,901529-FS1-4,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS,RO-disease_has_finding
502934678,7/14/2014 19:32:39,,1323051248,7/14/2014 19:31:35,neodev,0.7222,21752395,USA,"","",173.23.121.63,no_relation,106,33,,120,57,causes,0.577350269189626,901529-FS1-4,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS,RO-disease_has_finding
502934678,7/14/2014 19:33:03,,1323051473,7/14/2014 19:32:40,eup_slw,0.5952,20818028,GBR,A7,Birmingham,92.232.139.254,no_relation,106,33,,120,57,causes,0.577350269189626,901529-FS1-4,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS,RO-disease_has_finding
502934678,7/14/2014 19:40:35,,1323055930,7/14/2014 19:39:51,prodege,0.6667,22360212,GBR,I1,Luton,82.6.41.191,no_relation,106,33,,120,57,causes,0.577350269189626,901529-FS1-4,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS,RO-disease_has_finding
502934679,7/14/2014 17:01:30,,1322963995,7/14/2014 17:01:22,neodev,0.875,17610000,GBR,I2,Manchester,90.200.140.201,TUMOR (NEUROFIBROMA causes NEUROFIBROMATOSIS TYPE 1,96,0,,114,24,causes,0.987878339907213,906112-FS1-4,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502934679,7/14/2014 17:02:08,,1322964225,7/14/2014 17:01:49,clixsense,0.8194,27793793,GBR,C5,Chester,151.230.27.155,no_relation,96,0,,114,24,causes,0.987878339907213,906112-FS1-4,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502934679,7/14/2014 17:08:54,,1322967510,7/14/2014 17:08:48,neodev,0.6389,25224036,CAN,ON,Sudbury,67.204.218.187,TUMOR (NEUROFIBROMA causes NEUROFIBROMATOSIS TYPE 1,96,0,,114,24,causes,0.987878339907213,906112-FS1-4,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502934679,7/14/2014 17:28:13,,1322978201,7/14/2014 17:27:31,elite,0.5833,28276268,USA,MI,Taylor,67.149.247.166,NEUROFIBROMATOSIS TYPE 1 causes TUMOR (NEUROFIBROMA,96,0,,114,24,causes,0.987878339907213,906112-FS1-4,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502934679,7/14/2014 18:27:57,,1323014970,7/14/2014 18:27:38,neodev,0.6095,21515166,NLD,11,Nootdorp,83.86.58.179,NEUROFIBROMATOSIS TYPE 1 causes TUMOR (NEUROFIBROMA,96,0,,114,24,causes,0.987878339907213,906112-FS1-4,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502934679,7/14/2014 18:30:00,,1323015834,7/14/2014 18:29:33,instagc,0.6187,28524232,CAN,ON,Toronto,99.244.116.246,NEUROFIBROMATOSIS TYPE 1 causes TUMOR (NEUROFIBROMA,96,0,,114,24,causes,0.987878339907213,906112-FS1-4,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502934679,7/14/2014 18:49:41,,1323025099,7/14/2014 18:49:36,clixsense,0.4121,19162475,GBR,M3,Frome,82.33.126.30,NEUROFIBROMATOSIS TYPE 1 causes TUMOR (NEUROFIBROMA,96,0,,114,24,causes,0.987878339907213,906112-FS1-4,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1,RO-has_manifestation
502934680,7/14/2014 17:00:52,,1322963547,7/14/2014 17:00:32,clixsense,0.8611,27871219,NLD,07,Amsterdam,87.210.207.223,MIGRAINE causes TENSION TYPE HEADACHE,14,163,,34,171,causes,0.557086014531156,904906-FS1-4,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE,RO-has_definitional_manifestation
502934680,7/14/2014 17:01:21,,1322963905,7/14/2014 17:01:15,neodev,0.875,17610000,GBR,I2,Manchester,90.200.140.201,TENSION TYPE HEADACHE causes MIGRAINE,14,163,,34,171,causes,0.557086014531156,904906-FS1-4,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE,RO-has_definitional_manifestation
502934680,7/14/2014 17:01:48,,1322964154,7/14/2014 17:01:33,clixsense,0.8194,27793793,GBR,C5,Chester,151.230.27.155,MIGRAINE causes TENSION TYPE HEADACHE,14,163,,34,171,causes,0.557086014531156,904906-FS1-4,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE,RO-has_definitional_manifestation
502934680,7/14/2014 17:11:16,,1322968811,7/14/2014 17:10:50,instagc,0.5208,19636746,USA,NY,Andover,192.182.216.225,no_relation,14,163,,34,171,causes,0.557086014531156,904906-FS1-4,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE,RO-has_definitional_manifestation
502934680,7/14/2014 17:49:22,,1322996403,7/14/2014 17:48:54,prodege,0.6667,2143114,CAN,BC,Vancouver,24.84.160.12,TENSION TYPE HEADACHE causes MIGRAINE,14,163,,34,171,causes,0.557086014531156,904906-FS1-4,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE,RO-has_definitional_manifestation
502934680,7/14/2014 17:49:53,,1322996599,7/14/2014 17:49:33,clixsense,0.6389,19803139,NLD,06,Veldhoven,212.61.84.196,TENSION TYPE HEADACHE causes MIGRAINE,14,163,,34,171,causes,0.557086014531156,904906-FS1-4,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE,RO-has_definitional_manifestation
502934680,7/14/2014 17:59:59,,1323001190,7/14/2014 17:59:27,neodev,0.6641,28269997,GBR,H9,London,151.224.171.48,no_relation,14,163,,34,171,causes,0.557086014531156,904906-FS1-4,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE,RO-has_definitional_manifestation
502934681,7/14/2014 16:59:11,,1322962637,7/14/2014 16:59:07,instagc,1.0,27753923,GBR,"","",94.196.229.196,DRUG RESISTANT EPILEPSY causes ANTIEPILEPTIC DRUGS (AEDS),94,32,,116,58,causes,0.404519917477945,908168-FS1-4,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS),RO-may_treat
502934681,7/14/2014 17:26:24,,1322976815,7/14/2014 17:26:08,pokerowned,0.5639,18747884,USA,MI,Snover,209.40.219.170,ANTIEPILEPTIC DRUGS (AEDS) causes DRUG RESISTANT EPILEPSY,94,32,,116,58,causes,0.404519917477945,908168-FS1-4,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS),RO-may_treat
502934681,7/14/2014 17:50:05,,1322996677,7/14/2014 17:49:57,prodege,0.6667,2143114,CAN,BC,Vancouver,24.84.160.12,ANTIEPILEPTIC DRUGS (AEDS) causes DRUG RESISTANT EPILEPSY,94,32,,116,58,causes,0.404519917477945,908168-FS1-4,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS),RO-may_treat
502934681,7/14/2014 17:50:12,,1322996729,7/14/2014 17:49:54,clixsense,0.6389,19803139,NLD,06,Veldhoven,212.61.84.196,ANTIEPILEPTIC DRUGS (AEDS) causes DRUG RESISTANT EPILEPSY,94,32,,116,58,causes,0.404519917477945,908168-FS1-4,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS),RO-may_treat
502934681,7/14/2014 18:48:51,,1323024646,7/14/2014 18:48:32,instagc,0.5869,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,94,32,,116,58,causes,0.404519917477945,908168-FS1-4,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS),RO-may_treat
502934681,7/14/2014 18:57:05,,1323029465,7/14/2014 18:56:38,instagc,0.5877,19686223,CAN,BC,Surrey,184.65.16.6,no_relation,94,32,,116,58,causes,0.404519917477945,908168-FS1-4,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS),RO-may_treat
502934681,7/14/2014 19:17:58,,1323041965,7/14/2014 19:17:33,instagc,0.7278,13763729,USA,"","",75.182.89.225,no_relation,94,32,,116,58,causes,0.404519917477945,908168-FS1-4,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS),RO-may_treat
502934682,7/14/2014 17:02:08,,1322964227,7/14/2014 17:01:49,clixsense,0.8194,27793793,GBR,C5,Chester,151.230.27.155,CARIES causes BACTERIA,138,58,,145,64,causes,0.583459965991578,903870-FS1-4,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES,RO-has_causative_agent
502934682,7/14/2014 17:27:21,,1322977557,7/14/2014 17:27:08,pokerowned,0.5639,18747884,USA,MI,Snover,209.40.219.170,BACTERIA causes CARIES,138,58,,145,64,causes,0.583459965991578,903870-FS1-4,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES,RO-has_causative_agent
502934682,7/14/2014 18:03:20,,1323002687,7/14/2014 18:03:07,prodege,0.4264,12944140,GBR,I4,Mitcham,92.21.55.247,no_relation,138,58,,145,64,causes,0.583459965991578,903870-FS1-4,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES,RO-has_causative_agent
502934682,7/14/2014 18:07:25,,1323005933,7/14/2014 18:06:33,instagc,0.4639,28519532,USA,IA,Honey Creek,12.73.110.131,BACTERIA causes CARIES,138,58,,145,64,causes,0.583459965991578,903870-FS1-4,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES,RO-has_causative_agent
502934682,7/14/2014 18:09:10,,1323006774,7/14/2014 18:08:22,prodege,0.5502,7899370,USA,MI,Bay City,71.13.81.162,no_relation,138,58,,145,64,causes,0.583459965991578,903870-FS1-4,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES,RO-has_causative_agent
502934682,7/14/2014 18:31:19,,1323016454,7/14/2014 18:30:42,instagc,0.6187,28524232,CAN,ON,Toronto,99.244.116.246,no_relation,138,58,,145,64,causes,0.583459965991578,903870-FS1-4,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES,RO-has_causative_agent
502934682,7/14/2014 18:33:24,,1323017265,7/14/2014 18:33:08,clixsense,0.7071,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,138,58,,145,64,causes,0.583459965991578,903870-FS1-4,"Hence Balb/c mice can be used as an experimental model in CARIES research, provided that great care is taken in selecting and storing the BACTERIA",BACTERIA,CARIES,RO-has_causative_agent
502934683,7/14/2014 16:59:39,,1322962845,7/14/2014 16:59:28,instagc,1.0,27753923,GBR,"","",94.196.229.196,JOINTS is location of ARTHRITIS,27,0,,32,9,is location of,0.866025403784439,902293-FS1-9,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502934683,7/14/2014 17:01:02,,1322963648,7/14/2014 17:00:56,neodev,0.875,17610000,GBR,I2,Manchester,90.200.140.201,JOINTS is location of ARTHRITIS,27,0,,32,9,is location of,0.866025403784439,902293-FS1-9,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502934683,7/14/2014 17:58:39,,1323000666,7/14/2014 17:58:04,neodev,0.6641,28269997,GBR,H9,London,151.224.171.48,JOINTS is location of ARTHRITIS,27,0,,32,9,is location of,0.866025403784439,902293-FS1-9,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502934683,7/14/2014 18:10:47,,1323007584,7/14/2014 18:10:19,vivatic,0.605,25451531,GBR,"","",83.67.28.193,JOINTS is location of ARTHRITIS,27,0,,32,9,is location of,0.866025403784439,902293-FS1-9,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502934683,7/14/2014 19:19:23,,1323042893,7/14/2014 19:18:53,instagc,0.7278,13763729,USA,"","",75.182.89.225,JOINTS is location of ARTHRITIS,27,0,,32,9,is location of,0.866025403784439,902293-FS1-9,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502934683,7/14/2014 19:29:19,,1323048982,7/14/2014 19:29:03,neodev,0.6472,14861092,GBR,I2,Manchester,90.194.137.76,JOINTS is location of ARTHRITIS,27,0,,32,9,is location of,0.866025403784439,902293-FS1-9,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502934683,7/14/2014 19:33:31,,1323051742,7/14/2014 19:33:08,neodev,0.7222,21752395,USA,"","",173.23.121.63,JOINTS is location of ARTHRITIS,27,0,,32,9,is location of,0.866025403784439,902293-FS1-9,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502934684,7/14/2014 17:01:11,,1322963776,7/14/2014 17:01:00,clixsense,0.8194,27793793,GBR,C5,Chester,151.230.27.155,ANTIEPILEPTIC DRUGS (AEDS) treats DRUG RESISTANT EPILEPSY,94,32,,116,58,treats,0.674199862463242,908168-FS1-2,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS),RO-may_treat
502934684,7/14/2014 17:49:32,,1322996466,7/14/2014 17:49:23,prodege,0.6667,2143114,CAN,BC,Vancouver,24.84.160.12,ANTIEPILEPTIC DRUGS (AEDS) treats DRUG RESISTANT EPILEPSY,94,32,,116,58,treats,0.674199862463242,908168-FS1-2,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS),RO-may_treat
502934684,7/14/2014 18:02:16,,1323002248,7/14/2014 18:01:58,prodege,0.4264,12944140,GBR,I4,Mitcham,92.21.55.247,no_relation,94,32,,116,58,treats,0.674199862463242,908168-FS1-2,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS),RO-may_treat
502934684,7/14/2014 18:34:16,,1323017615,7/14/2014 18:33:55,clixsense,0.7071,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,94,32,,116,58,treats,0.674199862463242,908168-FS1-2,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS),RO-may_treat
502934684,7/14/2014 18:55:56,,1323028674,7/14/2014 18:55:00,instagc,0.5877,19686223,CAN,BC,Surrey,184.65.16.6,ANTIEPILEPTIC DRUGS (AEDS) treats DRUG RESISTANT EPILEPSY,94,32,,116,58,treats,0.674199862463242,908168-FS1-2,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS),RO-may_treat
502934684,7/14/2014 19:13:38,,1323039435,7/14/2014 19:13:12,elite,0.6234,28503042,USA,NJ,Woodbridge,54.191.150.115,ANTIEPILEPTIC DRUGS (AEDS) treats DRUG RESISTANT EPILEPSY,94,32,,116,58,treats,0.674199862463242,908168-FS1-2,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS),RO-may_treat
502934684,7/14/2014 19:29:58,,1323049396,7/14/2014 19:29:21,neodev,0.6472,14861092,GBR,I2,Manchester,90.194.137.76,ANTIEPILEPTIC DRUGS (AEDS) treats DRUG RESISTANT EPILEPSY,94,32,,116,58,treats,0.674199862463242,908168-FS1-2,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS),RO-may_treat
502934685,7/14/2014 16:59:43,,1322962865,7/14/2014 16:59:02,clixsense,0.8611,27871219,NLD,07,Amsterdam,87.210.207.223,no_relation,55,10,,88,30,treats,0.693375245281537,906484-FS1-2,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA,RO-has_manifestation
502934685,7/14/2014 17:08:31,,1322967283,7/14/2014 17:08:26,neodev,0.6389,25224036,CAN,ON,Sudbury,67.204.218.187,ACETABULAR DYSPLASIA treats DEVELOPMENTAL DYSPLASIA OF THE HIP,55,10,,88,30,treats,0.693375245281537,906484-FS1-2,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA,RO-has_manifestation
502934685,7/14/2014 17:23:01,,1322974588,7/14/2014 17:22:49,instagc,0.8125,18960682,GBR,"","",86.29.147.112,no_relation,55,10,,88,30,treats,0.693375245281537,906484-FS1-2,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA,RO-has_manifestation
502934685,7/14/2014 17:27:28,,1322977646,7/14/2014 17:27:10,elite,0.5833,28276268,USA,MI,Taylor,67.149.247.166,ACETABULAR DYSPLASIA treats DEVELOPMENTAL DYSPLASIA OF THE HIP,55,10,,88,30,treats,0.693375245281537,906484-FS1-2,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA,RO-has_manifestation
502934685,7/14/2014 17:27:38,,1322977764,7/14/2014 17:27:21,pokerowned,0.5639,18747884,USA,MI,Snover,209.40.219.170,no_relation,55,10,,88,30,treats,0.693375245281537,906484-FS1-2,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA,RO-has_manifestation
502934685,7/14/2014 18:33:53,,1323017432,7/14/2014 18:33:41,clixsense,0.7071,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,55,10,,88,30,treats,0.693375245281537,906484-FS1-2,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA,RO-has_manifestation
502934685,7/14/2014 18:49:49,,1323025171,7/14/2014 18:49:22,instagc,0.5869,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,55,10,,88,30,treats,0.693375245281537,906484-FS1-2,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA,RO-has_manifestation
502934686,7/14/2014 17:02:31,,1322964447,7/14/2014 17:02:14,clixsense,0.8194,27793793,GBR,C5,Chester,151.230.27.155,MILD TRANSIENT RESPIRATORY DISTRESS causes RESPIRATORY DISTRESS SYNDROME,122,209,,156,238,causes,0.635000635000953,901937-FS1-4,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME,RO-disease_has_finding
502934686,7/14/2014 18:03:40,,1323002872,7/14/2014 18:03:21,prodege,0.4264,12944140,GBR,I4,Mitcham,92.21.55.247,no_relation,122,209,,156,238,causes,0.635000635000953,901937-FS1-4,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME,RO-disease_has_finding
502934686,7/14/2014 18:30:41,,1323016169,7/14/2014 18:30:00,instagc,0.6187,28524232,CAN,ON,Toronto,99.244.116.246,no_relation,122,209,,156,238,causes,0.635000635000953,901937-FS1-4,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME,RO-disease_has_finding
502934686,7/14/2014 18:58:01,,1323030192,7/14/2014 18:57:06,instagc,0.5877,19686223,CAN,BC,Surrey,184.65.16.6,MILD TRANSIENT RESPIRATORY DISTRESS causes RESPIRATORY DISTRESS SYNDROME,122,209,,156,238,causes,0.635000635000953,901937-FS1-4,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME,RO-disease_has_finding
502934686,7/14/2014 19:19:23,,1323042894,7/14/2014 19:18:53,instagc,0.7278,13763729,USA,"","",75.182.89.225,no_relation,122,209,,156,238,causes,0.635000635000953,901937-FS1-4,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME,RO-disease_has_finding
502934686,7/14/2014 19:30:23,,1323049719,7/14/2014 19:29:59,neodev,0.6472,14861092,GBR,I2,Manchester,90.194.137.76,no_relation,122,209,,156,238,causes,0.635000635000953,901937-FS1-4,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME,RO-disease_has_finding
502934686,7/14/2014 19:32:08,,1323050955,7/14/2014 19:31:23,clixsense,0.3921,15189335,GBR,A7,Birmingham,94.197.121.232,RESPIRATORY DISTRESS SYNDROME causes MILD TRANSIENT RESPIRATORY DISTRESS,122,209,,156,238,causes,0.635000635000953,901937-FS1-4,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME,RO-disease_has_finding
502934687,7/14/2014 17:00:31,,1322963238,7/14/2014 16:59:44,clixsense,0.8611,27871219,NLD,07,Amsterdam,87.210.207.223,TUBERCULOSIS diagnosed by PPD SKIN TEST,296,322,,307,335,diagnosed by,0.936329177569044,906759-FS1-13,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST,RO-may_diagnose
502934687,7/14/2014 17:08:38,,1322967362,7/14/2014 17:08:32,neodev,0.6389,25224036,CAN,ON,Sudbury,67.204.218.187,PPD SKIN TEST diagnosed by TUBERCULOSIS,296,322,,307,335,diagnosed by,0.936329177569044,906759-FS1-13,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST,RO-may_diagnose
502934687,7/14/2014 17:27:07,,1322977418,7/14/2014 17:26:53,pokerowned,0.5639,18747884,USA,MI,Snover,209.40.219.170,TUBERCULOSIS diagnosed by PPD SKIN TEST,296,322,,307,335,diagnosed by,0.936329177569044,906759-FS1-13,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST,RO-may_diagnose
502934687,7/14/2014 17:50:31,,1322996901,7/14/2014 17:50:12,clixsense,0.6389,19803139,NLD,06,Veldhoven,212.61.84.196,TUBERCULOSIS diagnosed by PPD SKIN TEST,296,322,,307,335,diagnosed by,0.936329177569044,906759-FS1-13,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST,RO-may_diagnose
502934687,7/14/2014 18:29:12,,1323015525,7/14/2014 18:28:54,neodev,0.6095,21515166,NLD,11,Nootdorp,83.86.58.179,TUBERCULOSIS diagnosed by PPD SKIN TEST,296,322,,307,335,diagnosed by,0.936329177569044,906759-FS1-13,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST,RO-may_diagnose
502934687,7/14/2014 18:49:21,,1323024918,7/14/2014 18:49:09,instagc,0.5869,25990856,USA,NV,Las Vegas,68.108.98.78,PPD SKIN TEST diagnosed by TUBERCULOSIS,296,322,,307,335,diagnosed by,0.936329177569044,906759-FS1-13,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST,RO-may_diagnose
502934687,7/14/2014 18:49:35,,1323025062,7/14/2014 18:49:25,clixsense,0.4121,19162475,GBR,M3,Frome,82.33.126.30,PPD SKIN TEST diagnosed by TUBERCULOSIS,296,322,,307,335,diagnosed by,0.936329177569044,906759-FS1-13,"Lower fracture risk by arranging for home safety assessment and devices to improve gait stability, and by recommending tai chi or other balance exercises Arrange periodic ophthalmologic screening for cataracts (posterior subcapsular) and glaucoma to detect vision loss Anticipate reactivation of TUBERCULOSIS and obtain a PPD SKIN TEST before beginning high dose steroid therapy Recommend dietary modification to avoid weight gain and to monitor for hyperglycemic symptoms.",TUBERCULOSIS,PPD SKIN TEST,RO-may_diagnose
502934688,7/14/2014 16:59:46,,1322962877,7/14/2014 16:59:41,instagc,1.0,27753923,GBR,"","",94.196.229.196,HEPATOMA treats ASCITES FLUID,74,106,,86,114,treats,0.338061701891407,902852-FS1-2,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA,RO-disease_may_have_finding
502934688,7/14/2014 17:49:32,,1322996462,7/14/2014 17:49:19,clixsense,0.6389,19803139,NLD,06,Veldhoven,212.61.84.196,ASCITES FLUID treats HEPATOMA,74,106,,86,114,treats,0.338061701891407,902852-FS1-2,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA,RO-disease_may_have_finding
502934688,7/14/2014 18:22:39,,1323012800,7/14/2014 18:21:55,instagc,0.6187,28524232,CAN,ON,Toronto,99.244.116.246,no_relation,74,106,,86,114,treats,0.338061701891407,902852-FS1-2,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA,RO-disease_may_have_finding
502934688,7/14/2014 18:33:40,,1323017392,7/14/2014 18:33:24,clixsense,0.7071,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,74,106,,86,114,treats,0.338061701891407,902852-FS1-2,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA,RO-disease_may_have_finding
502934688,7/14/2014 18:49:07,,1323024788,7/14/2014 18:48:52,instagc,0.5869,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,74,106,,86,114,treats,0.338061701891407,902852-FS1-2,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA,RO-disease_may_have_finding
502934688,7/14/2014 18:49:35,,1323025063,7/14/2014 18:49:25,clixsense,0.4121,19162475,GBR,M3,Frome,82.33.126.30,HEPATOMA treats ASCITES FLUID,74,106,,86,114,treats,0.338061701891407,902852-FS1-2,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA,RO-disease_may_have_finding
502934688,7/14/2014 18:55:56,,1323028675,7/14/2014 18:55:00,instagc,0.5877,19686223,CAN,BC,Surrey,184.65.16.6,ASCITES FLUID treats HEPATOMA,74,106,,86,114,treats,0.338061701891407,902852-FS1-2,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA,RO-disease_may_have_finding
502934689,7/14/2014 16:59:00,,1322962575,7/14/2014 16:58:55,instagc,1.0,27753923,GBR,"","",94.196.229.196,IRON DEFICIENCY ANEMIA treats EPOETIN ALFA THERAPY,210,268,,231,288,treats,0.980196058819607,907636-FS1-2,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY,RO-may_treat
502934689,7/14/2014 17:08:47,,1322967438,7/14/2014 17:08:42,neodev,0.6389,25224036,CAN,ON,Sudbury,67.204.218.187,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,210,268,,231,288,treats,0.980196058819607,907636-FS1-2,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY,RO-may_treat
502934689,7/14/2014 17:22:36,,1322974312,7/14/2014 17:22:25,instagc,0.8125,18960682,GBR,"","",86.29.147.112,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,210,268,,231,288,treats,0.980196058819607,907636-FS1-2,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY,RO-may_treat
502934689,7/14/2014 18:06:59,,1323005728,7/14/2014 18:05:53,prodege,0.5502,7899370,USA,MI,Bay City,71.13.81.162,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,210,268,,231,288,treats,0.980196058819607,907636-FS1-2,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY,RO-may_treat
502934689,7/14/2014 18:31:19,,1323016425,7/14/2014 18:30:42,instagc,0.6187,28524232,CAN,ON,Toronto,99.244.116.246,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,210,268,,231,288,treats,0.980196058819607,907636-FS1-2,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY,RO-may_treat
502934689,7/14/2014 18:46:23,,1323023344,7/14/2014 18:46:14,clixsense,0.4121,19162475,GBR,M3,Frome,82.33.126.30,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,210,268,,231,288,treats,0.980196058819607,907636-FS1-2,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY,RO-may_treat
502934689,7/14/2014 19:31:01,,1323050047,7/14/2014 19:30:45,neodev,0.6472,14861092,GBR,I2,Manchester,90.194.137.76,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,210,268,,231,288,treats,0.980196058819607,907636-FS1-2,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY,RO-may_treat
502934690,7/14/2014 17:01:11,,1322963777,7/14/2014 17:01:00,clixsense,0.8194,27793793,GBR,C5,Chester,151.230.27.155,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,81,113,,103,125,causes,0.821994936526786,901889-FS1-4,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA,RO-disease_has_finding
502934690,7/14/2014 17:11:16,,1322968814,7/14/2014 17:10:50,instagc,0.5208,19636746,USA,NY,Andover,192.182.216.225,no_relation,81,113,,103,125,causes,0.821994936526786,901889-FS1-4,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA,RO-disease_has_finding
502934690,7/14/2014 17:26:40,,1322977026,7/14/2014 17:26:26,pokerowned,0.5639,18747884,USA,MI,Snover,209.40.219.170,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,81,113,,103,125,causes,0.821994936526786,901889-FS1-4,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA,RO-disease_has_finding
502934690,7/14/2014 17:29:09,,1322978912,7/14/2014 17:28:15,elite,0.5833,28276268,USA,MI,Taylor,67.149.247.166,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,81,113,,103,125,causes,0.821994936526786,901889-FS1-4,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA,RO-disease_has_finding
502934690,7/14/2014 18:10:17,,1323007283,7/14/2014 18:09:43,vivatic,0.605,25451531,GBR,"","",83.67.28.193,no_relation,81,113,,103,125,causes,0.821994936526786,901889-FS1-4,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA,RO-disease_has_finding
502934690,7/14/2014 18:28:33,,1323015274,7/14/2014 18:28:13,neodev,0.6095,21515166,NLD,11,Nootdorp,83.86.58.179,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,81,113,,103,125,causes,0.821994936526786,901889-FS1-4,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA,RO-disease_has_finding
502934690,7/14/2014 18:33:07,,1323017192,7/14/2014 18:32:50,clixsense,0.7071,16827630,GBR,A7,Birmingham,86.146.169.103,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,81,113,,103,125,causes,0.821994936526786,901889-FS1-4,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA,RO-disease_has_finding
502934691,7/14/2014 17:01:55,,1322964194,7/14/2014 17:01:24,clixsense,0.8611,27871219,NLD,07,Amsterdam,87.210.207.223,POLYPOID LESION diagnosed by GASTRO INTESTINAL POLYPS,106,33,,120,57,diagnosed by,0.38490017945975,901529-FS1-13,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS,RO-disease_has_finding
502934691,7/14/2014 17:50:57,,1322997096,7/14/2014 17:50:32,clixsense,0.6389,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,106,33,,120,57,diagnosed by,0.38490017945975,901529-FS1-13,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS,RO-disease_has_finding
502934691,7/14/2014 18:02:58,,1323002569,7/14/2014 18:02:46,prodege,0.4264,12944140,GBR,I4,Mitcham,92.21.55.247,no_relation,106,33,,120,57,diagnosed by,0.38490017945975,901529-FS1-13,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS,RO-disease_has_finding
502934691,7/14/2014 18:09:47,,1323007061,7/14/2014 18:09:18,instagc,0.4639,28519532,USA,IA,Honey Creek,12.73.110.131,GASTRO INTESTINAL POLYPS diagnosed by POLYPOID LESION,106,33,,120,57,diagnosed by,0.38490017945975,901529-FS1-13,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS,RO-disease_has_finding
502934691,7/14/2014 18:46:53,,1323023628,7/14/2014 18:46:24,clixsense,0.4121,19162475,GBR,M3,Frome,82.33.126.30,GASTRO INTESTINAL POLYPS diagnosed by POLYPOID LESION,106,33,,120,57,diagnosed by,0.38490017945975,901529-FS1-13,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS,RO-disease_has_finding
502934691,7/14/2014 19:20:21,,1323043507,7/14/2014 19:19:24,instagc,0.7278,13763729,USA,"","",75.182.89.225,GASTRO INTESTINAL POLYPS diagnosed by POLYPOID LESION,106,33,,120,57,diagnosed by,0.38490017945975,901529-FS1-13,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS,RO-disease_has_finding
502934691,7/14/2014 19:29:19,,1323048975,7/14/2014 19:29:03,neodev,0.6472,14861092,GBR,I2,Manchester,90.194.137.76,GASTRO INTESTINAL POLYPS diagnosed by POLYPOID LESION,106,33,,120,57,diagnosed by,0.38490017945975,901529-FS1-13,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS,RO-disease_has_finding
502934692,7/14/2014 17:01:37,,1322964051,7/14/2014 17:01:31,neodev,0.875,17610000,GBR,I2,Manchester,90.200.140.201,PELVIC PAIN causes ENDOMETRIOSIS,64,86,,74,99,causes,0.995893206467704,904571-FS1-4,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS,RO-has_definitional_manifestation
502934692,7/14/2014 18:10:16,,1323007273,7/14/2014 18:09:58,prodege,0.5502,7899370,USA,MI,Bay City,71.13.81.162,ENDOMETRIOSIS causes PELVIC PAIN,64,86,,74,99,causes,0.995893206467704,904571-FS1-4,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS,RO-has_definitional_manifestation
502934692,7/14/2014 18:14:37,,1323009339,7/14/2014 18:13:55,instagc,0.4639,28519532,USA,IA,Honey Creek,12.73.110.131,ENDOMETRIOSIS causes PELVIC PAIN,64,86,,74,99,causes,0.995893206467704,904571-FS1-4,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS,RO-has_definitional_manifestation
502934692,7/14/2014 18:28:13,,1323015101,7/14/2014 18:27:58,neodev,0.6095,21515166,NLD,11,Nootdorp,83.86.58.179,ENDOMETRIOSIS causes PELVIC PAIN,64,86,,74,99,causes,0.995893206467704,904571-FS1-4,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS,RO-has_definitional_manifestation
502934692,7/14/2014 18:33:53,,1323017433,7/14/2014 18:33:41,clixsense,0.7071,16827630,GBR,A7,Birmingham,86.146.169.103,ENDOMETRIOSIS causes PELVIC PAIN,64,86,,74,99,causes,0.995893206467704,904571-FS1-4,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS,RO-has_definitional_manifestation
502934692,7/14/2014 19:18:52,,1323042560,7/14/2014 19:18:28,instagc,0.7278,13763729,USA,"","",75.182.89.225,ENDOMETRIOSIS causes PELVIC PAIN,64,86,,74,99,causes,0.995893206467704,904571-FS1-4,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS,RO-has_definitional_manifestation
502934692,7/14/2014 19:29:02,,1323048812,7/14/2014 19:28:47,neodev,0.6472,14861092,GBR,I2,Manchester,90.194.137.76,ENDOMETRIOSIS causes PELVIC PAIN,64,86,,74,99,causes,0.995893206467704,904571-FS1-4,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS,RO-has_definitional_manifestation
502934693,7/14/2014 16:59:43,,1322962866,7/14/2014 16:59:02,clixsense,0.8611,27871219,NLD,07,Amsterdam,87.210.207.223,no_relation,102,138,,116,159,causes,0.768221279597376,904998-FS1-4,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA,RO-has_definitional_manifestation
502934693,7/14/2014 18:33:24,,1323017266,7/14/2014 18:33:08,clixsense,0.7071,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,102,138,,116,159,causes,0.768221279597376,904998-FS1-4,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA,RO-has_definitional_manifestation
502934693,7/14/2014 18:46:53,,1323023627,7/14/2014 18:46:24,clixsense,0.4121,19162475,GBR,M3,Frome,82.33.126.30,MICROSCOPIC HEMATURIA causes GROSS HEMATURIA,102,138,,116,159,causes,0.768221279597376,904998-FS1-4,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA,RO-has_definitional_manifestation
502934693,7/14/2014 18:50:38,,1323025632,7/14/2014 18:50:14,instagc,0.5869,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,102,138,,116,159,causes,0.768221279597376,904998-FS1-4,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA,RO-has_definitional_manifestation
502934693,7/14/2014 19:18:27,,1323042287,7/14/2014 19:17:58,instagc,0.7278,13763729,USA,"","",75.182.89.225,no_relation,102,138,,116,159,causes,0.768221279597376,904998-FS1-4,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA,RO-has_definitional_manifestation
502934693,7/14/2014 19:31:21,,1323050443,7/14/2014 19:30:54,clixsense,0.3921,15189335,GBR,A7,Birmingham,94.197.121.232,MICROSCOPIC HEMATURIA causes GROSS HEMATURIA,102,138,,116,159,causes,0.768221279597376,904998-FS1-4,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA,RO-has_definitional_manifestation
502934693,7/14/2014 19:33:31,,1323051722,7/14/2014 19:33:08,neodev,0.7222,21752395,USA,"","",173.23.121.63,no_relation,102,138,,116,159,causes,0.768221279597376,904998-FS1-4,"ISOLATED HEMATURIA  Hematuria is RBCs in urine; the urine may be red (macroscopic hematuria), bloody (GROSS HEMATURIA) or not discolored (MICROSCOPIC HEMATURIA).",GROSS HEMATURIA,MICROSCOPIC HEMATURIA,RO-has_definitional_manifestation
502934694,7/14/2014 17:22:48,,1322974430,7/14/2014 17:22:38,instagc,0.8125,18960682,GBR,"","",86.29.147.112,BACILLUS ANTHRACIS causes ANTHRAX,0,78,,17,85,causes,0.995037190209989,903926-FS1-4,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX,RO-has_causative_agent
502934694,7/14/2014 18:49:07,,1323024806,7/14/2014 18:48:52,instagc,0.5869,25990856,USA,NV,Las Vegas,68.108.98.78,BACILLUS ANTHRACIS causes ANTHRAX,0,78,,17,85,causes,0.995037190209989,903926-FS1-4,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX,RO-has_causative_agent
502934694,7/14/2014 18:59:02,,1323030871,7/14/2014 18:58:03,instagc,0.5877,19686223,CAN,BC,Surrey,184.65.16.6,BACILLUS ANTHRACIS causes ANTHRAX,0,78,,17,85,causes,0.995037190209989,903926-FS1-4,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX,RO-has_causative_agent
502934694,7/14/2014 19:17:58,,1323041967,7/14/2014 19:17:33,instagc,0.7278,13763729,USA,"","",75.182.89.225,BACILLUS ANTHRACIS causes ANTHRAX,0,78,,17,85,causes,0.995037190209989,903926-FS1-4,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX,RO-has_causative_agent
502934694,7/14/2014 19:30:28,,1323049744,7/14/2014 19:30:15,clixsense,0.3921,15189335,GBR,A7,Birmingham,94.197.121.232,ANTHRAX causes BACILLUS ANTHRACIS,0,78,,17,85,causes,0.995037190209989,903926-FS1-4,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX,RO-has_causative_agent
502934694,7/14/2014 19:32:39,,1323051261,7/14/2014 19:32:17,eup_slw,0.5952,20818028,GBR,A7,Birmingham,92.232.139.254,BACILLUS ANTHRACIS causes ANTHRAX,0,78,,17,85,causes,0.995037190209989,903926-FS1-4,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX,RO-has_causative_agent
502934694,7/14/2014 19:33:41,,1323051861,7/14/2014 19:33:32,neodev,0.7222,21752395,USA,"","",173.23.121.63,BACILLUS ANTHRACIS causes ANTHRAX,0,78,,17,85,causes,0.995037190209989,903926-FS1-4,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX,RO-has_causative_agent
502934695,7/14/2014 18:10:17,,1323007282,7/14/2014 18:09:43,vivatic,0.605,25451531,GBR,"","",83.67.28.193,no_relation,0,44,,15,81,treats,0.884651736929383,908161-FS1-2,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN,RO-may_treat
502934695,7/14/2014 18:34:16,,1323017618,7/14/2014 18:33:55,clixsense,0.7071,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,0,44,,15,81,treats,0.884651736929383,908161-FS1-2,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN,RO-may_treat
502934695,7/14/2014 18:49:49,,1323025166,7/14/2014 18:49:22,instagc,0.5869,25990856,USA,NV,Las Vegas,68.108.98.78,(CYA METHOTREXATE AND PREDNISONE (PDN treats GVHD PROPHYLAXIS,0,44,,15,81,treats,0.884651736929383,908161-FS1-2,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN,RO-may_treat
502934695,7/14/2014 19:14:41,,1323040016,7/14/2014 19:14:06,elite,0.6234,28503042,USA,NJ,Woodbridge,54.191.150.115,(CYA METHOTREXATE AND PREDNISONE (PDN treats GVHD PROPHYLAXIS,0,44,,15,81,treats,0.884651736929383,908161-FS1-2,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN,RO-may_treat
502934695,7/14/2014 19:18:52,,1323042562,7/14/2014 19:18:28,instagc,0.7278,13763729,USA,"","",75.182.89.225,(CYA METHOTREXATE AND PREDNISONE (PDN treats GVHD PROPHYLAXIS,0,44,,15,81,treats,0.884651736929383,908161-FS1-2,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN,RO-may_treat
502934695,7/14/2014 19:30:44,,1323049891,7/14/2014 19:30:24,neodev,0.6472,14861092,GBR,I2,Manchester,90.194.137.76,no_relation,0,44,,15,81,treats,0.884651736929383,908161-FS1-2,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN,RO-may_treat
502934695,7/14/2014 19:31:34,,1323050589,7/14/2014 19:30:53,neodev,0.7222,21752395,USA,"","",173.23.121.63,no_relation,0,44,,15,81,treats,0.884651736929383,908161-FS1-2,GVHD PROPHYLAXIS was done with cyclosporine (CYA METHOTREXATE AND PREDNISONE (PDN.,GVHD PROPHYLAXIS,(CYA METHOTREXATE AND PREDNISONE (PDN,RO-may_treat
502934696,7/14/2014 17:01:22,,1322963922,7/14/2014 17:00:53,clixsense,0.8611,27871219,NLD,07,Amsterdam,87.210.207.223,no_relation,132,85,,173,103,causes,0.365148371670111,906409-FS1-4,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA,RO-has_manifestation
502934696,7/14/2014 18:10:47,,1323007587,7/14/2014 18:10:19,vivatic,0.605,25451531,GBR,"","",83.67.28.193,no_relation,132,85,,173,103,causes,0.365148371670111,906409-FS1-4,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA,RO-has_manifestation
502934696,7/14/2014 18:28:13,,1323015102,7/14/2014 18:27:58,neodev,0.6095,21515166,NLD,11,Nootdorp,83.86.58.179,POLYCYTHAEMIA VERA causes THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,132,85,,173,103,causes,0.365148371670111,906409-FS1-4,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA,RO-has_manifestation
502934696,7/14/2014 18:50:38,,1323025631,7/14/2014 18:50:14,instagc,0.5869,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,132,85,,173,103,causes,0.365148371670111,906409-FS1-4,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA,RO-has_manifestation
502934696,7/14/2014 19:15:30,,1323040432,7/14/2014 19:15:12,elite,0.6234,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,132,85,,173,103,causes,0.365148371670111,906409-FS1-4,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA,RO-has_manifestation
502934696,7/14/2014 19:30:53,,1323049973,7/14/2014 19:30:31,clixsense,0.3921,15189335,GBR,A7,Birmingham,94.197.121.232,POLYCYTHAEMIA VERA causes THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,132,85,,173,103,causes,0.365148371670111,906409-FS1-4,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA,RO-has_manifestation
502934696,7/14/2014 19:33:28,,1323051694,7/14/2014 19:33:05,eup_slw,0.5952,20818028,GBR,A7,Birmingham,92.232.139.254,no_relation,132,85,,173,103,causes,0.365148371670111,906409-FS1-4,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA,RO-has_manifestation
502934697,7/14/2014 17:01:22,,1322963921,7/14/2014 17:00:53,clixsense,0.8611,27871219,NLD,07,Amsterdam,87.210.207.223,no_relation,201,133,,225,164,causes,0.64888568452305,906678-FS1-4,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION,RO-may_diagnose
502934697,7/14/2014 17:02:41,,1322964496,7/14/2014 17:02:32,clixsense,0.8194,27793793,GBR,C5,Chester,151.230.27.155,no_relation,201,133,,225,164,causes,0.64888568452305,906678-FS1-4,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION,RO-may_diagnose
502934697,7/14/2014 17:23:21,,1322974793,7/14/2014 17:23:03,instagc,0.8125,18960682,GBR,"","",86.29.147.112,no_relation,201,133,,225,164,causes,0.64888568452305,906678-FS1-4,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION,RO-may_diagnose
502934697,7/14/2014 17:26:24,,1322976819,7/14/2014 17:26:08,pokerowned,0.5639,18747884,USA,MI,Snover,209.40.219.170,SINGLE METHACHOLINE STIMULATION causes BRONCHIAL HYPERREACTIVITY,201,133,,225,164,causes,0.64888568452305,906678-FS1-4,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION,RO-may_diagnose
502934697,7/14/2014 18:03:40,,1323002870,7/14/2014 18:03:21,prodege,0.4264,12944140,GBR,I4,Mitcham,92.21.55.247,no_relation,201,133,,225,164,causes,0.64888568452305,906678-FS1-4,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION,RO-may_diagnose
502934697,7/14/2014 18:07:41,,1323006028,7/14/2014 18:06:56,vivatic,0.605,25451531,GBR,"","",83.67.28.193,no_relation,201,133,,225,164,causes,0.64888568452305,906678-FS1-4,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION,RO-may_diagnose
502934697,7/14/2014 18:29:12,,1323015518,7/14/2014 18:28:54,neodev,0.6095,21515166,NLD,11,Nootdorp,83.86.58.179,SINGLE METHACHOLINE STIMULATION causes BRONCHIAL HYPERREACTIVITY,201,133,,225,164,causes,0.64888568452305,906678-FS1-4,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION,RO-may_diagnose
502934698,7/14/2014 17:02:31,,1322964445,7/14/2014 17:02:14,clixsense,0.8194,27793793,GBR,C5,Chester,151.230.27.155,FRUCTOSE INTOLERANCE causes DEFICIT OF THE LIVER,36,0,,55,20,causes,1,906249-FS1-4,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE,RO-has_manifestation
502934698,7/14/2014 17:08:47,,1322967440,7/14/2014 17:08:42,neodev,0.6389,25224036,CAN,ON,Sudbury,67.204.218.187,FRUCTOSE INTOLERANCE causes DEFICIT OF THE LIVER,36,0,,55,20,causes,1,906249-FS1-4,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE,RO-has_manifestation
502934698,7/14/2014 17:49:32,,1322996464,7/14/2014 17:49:23,prodege,0.6667,2143114,CAN,BC,Vancouver,24.84.160.12,FRUCTOSE INTOLERANCE causes DEFICIT OF THE LIVER,36,0,,55,20,causes,1,906249-FS1-4,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE,RO-has_manifestation
502934698,7/14/2014 18:08:46,,1323006557,7/14/2014 18:08:18,vivatic,0.605,25451531,GBR,"","",83.67.28.193,DEFICIT OF THE LIVER causes FRUCTOSE INTOLERANCE,36,0,,55,20,causes,1,906249-FS1-4,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE,RO-has_manifestation
502934698,7/14/2014 19:15:10,,1323040244,7/14/2014 19:14:43,elite,0.6234,28503042,USA,NJ,Woodbridge,54.191.150.115,FRUCTOSE INTOLERANCE causes DEFICIT OF THE LIVER,36,0,,55,20,causes,1,906249-FS1-4,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE,RO-has_manifestation
502934698,7/14/2014 19:29:02,,1323048817,7/14/2014 19:28:47,neodev,0.6472,14861092,GBR,I2,Manchester,90.194.137.76,DEFICIT OF THE LIVER causes FRUCTOSE INTOLERANCE,36,0,,55,20,causes,1,906249-FS1-4,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE,RO-has_manifestation
502934698,7/14/2014 19:29:48,,1323049322,7/14/2014 19:29:22,clixsense,0.3921,15189335,GBR,A7,Birmingham,94.197.121.232,DEFICIT OF THE LIVER causes FRUCTOSE INTOLERANCE,36,0,,55,20,causes,1,906249-FS1-4,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE,RO-has_manifestation
502934699,7/14/2014 17:08:25,,1322967233,7/14/2014 17:08:20,neodev,0.6389,25224036,CAN,ON,Sudbury,67.204.218.187,INHERITED RICKETS causes VITAMIN D,143,188,,159,197,causes,0.685994340570035,908221-FS1-4,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D,RO-may_treat
502934699,7/14/2014 17:12:36,,1322969556,7/14/2014 17:12:22,instagc,0.5208,19636746,USA,NY,Andover,192.182.216.225,no_relation,143,188,,159,197,causes,0.685994340570035,908221-FS1-4,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D,RO-may_treat
502934699,7/14/2014 17:49:56,,1322996619,7/14/2014 17:49:45,prodege,0.6667,2143114,CAN,BC,Vancouver,24.84.160.12,VITAMIN D causes INHERITED RICKETS,143,188,,159,197,causes,0.685994340570035,908221-FS1-4,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D,RO-may_treat
502934699,7/14/2014 17:50:12,,1322996728,7/14/2014 17:49:54,clixsense,0.6389,19803139,NLD,06,Veldhoven,212.61.84.196,VITAMIN D causes INHERITED RICKETS,143,188,,159,197,causes,0.685994340570035,908221-FS1-4,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D,RO-may_treat
502934699,7/14/2014 18:01:00,,1323001726,7/14/2014 18:00:33,neodev,0.6641,28269997,GBR,H9,London,151.224.171.48,no_relation,143,188,,159,197,causes,0.685994340570035,908221-FS1-4,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D,RO-may_treat
502934699,7/14/2014 18:07:57,,1323006135,7/14/2014 18:07:31,instagc,0.4639,28519532,USA,IA,Honey Creek,12.73.110.131,no_relation,143,188,,159,197,causes,0.685994340570035,908221-FS1-4,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D,RO-may_treat
502934699,7/14/2014 18:09:42,,1323007006,7/14/2014 18:08:47,vivatic,0.605,25451531,GBR,"","",83.67.28.193,no_relation,143,188,,159,197,causes,0.685994340570035,908221-FS1-4,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D,RO-may_treat
502934700,7/14/2014 17:23:01,,1322974585,7/14/2014 17:22:49,instagc,0.8125,18960682,GBR,"","",86.29.147.112,no_relation,74,106,,86,114,causes,0.676123403782813,902852-FS1-4,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA,RO-disease_may_have_finding
502934700,7/14/2014 17:49:53,,1322996600,7/14/2014 17:49:33,clixsense,0.6389,19803139,NLD,06,Veldhoven,212.61.84.196,HEPATOMA causes ASCITES FLUID,74,106,,86,114,causes,0.676123403782813,902852-FS1-4,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA,RO-disease_may_have_finding
502934700,7/14/2014 19:14:04,,1323039639,7/14/2014 19:13:40,elite,0.6234,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,74,106,,86,114,causes,0.676123403782813,902852-FS1-4,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA,RO-disease_may_have_finding
502934700,7/14/2014 19:30:28,,1323049743,7/14/2014 19:30:15,clixsense,0.3921,15189335,GBR,A7,Birmingham,94.197.121.232,ASCITES FLUID causes HEPATOMA,74,106,,86,114,causes,0.676123403782813,902852-FS1-4,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA,RO-disease_may_have_finding
502934700,7/14/2014 19:30:44,,1323049892,7/14/2014 19:30:24,neodev,0.6472,14861092,GBR,I2,Manchester,90.194.137.76,no_relation,74,106,,86,114,causes,0.676123403782813,902852-FS1-4,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA,RO-disease_may_have_finding
502934700,7/14/2014 19:33:07,,1323051504,7/14/2014 19:32:40,neodev,0.7222,21752395,USA,"","",173.23.121.63,no_relation,74,106,,86,114,causes,0.676123403782813,902852-FS1-4,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA,RO-disease_may_have_finding
502934700,7/14/2014 19:33:28,,1323051695,7/14/2014 19:33:05,eup_slw,0.5952,20818028,GBR,A7,Birmingham,92.232.139.254,HEPATOMA causes ASCITES FLUID,74,106,,86,114,causes,0.676123403782813,902852-FS1-4,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA,RO-disease_may_have_finding
502934701,7/14/2014 17:01:08,,1322963734,7/14/2014 17:01:03,neodev,0.875,17610000,GBR,I2,Manchester,90.200.140.201,LEFT VENTRICULAR HYPERTROPHY treats RAMIPRIL,147,55,,174,63,treats,1,907265-FS1-2,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL,RO-may_prevent
502934701,7/14/2014 17:02:21,,1322964374,7/14/2014 17:01:56,clixsense,0.8611,27871219,NLD,07,Amsterdam,87.210.207.223,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,147,55,,174,63,treats,1,907265-FS1-2,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL,RO-may_prevent
502934701,7/14/2014 17:12:21,,1322969406,7/14/2014 17:11:45,instagc,0.5208,19636746,USA,NY,Andover,192.182.216.225,no_relation,147,55,,174,63,treats,1,907265-FS1-2,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL,RO-may_prevent
502934701,7/14/2014 17:23:21,,1322974795,7/14/2014 17:23:03,instagc,0.8125,18960682,GBR,"","",86.29.147.112,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,147,55,,174,63,treats,1,907265-FS1-2,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL,RO-may_prevent
502934701,7/14/2014 17:59:26,,1323000980,7/14/2014 17:58:40,neodev,0.6641,28269997,GBR,H9,London,151.224.171.48,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,147,55,,174,63,treats,1,907265-FS1-2,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL,RO-may_prevent
502934701,7/14/2014 18:08:21,,1323006359,7/14/2014 18:07:56,prodege,0.5502,7899370,USA,MI,Bay City,71.13.81.162,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,147,55,,174,63,treats,1,907265-FS1-2,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL,RO-may_prevent
502934701,7/14/2014 18:29:18,,1323015541,7/14/2014 18:28:56,instagc,0.6187,28524232,CAN,ON,Toronto,99.244.116.246,RAMIPRIL treats LEFT VENTRICULAR HYPERTROPHY,147,55,,174,63,treats,1,907265-FS1-2,"In rats with a coronary occlusion of 6 weeks duration, RAMIPRIL administration significantly reduced infarct size and prevented the development of LEFT VENTRICULAR HYPERTROPHY",LEFT VENTRICULAR HYPERTROPHY,RAMIPRIL,RO-may_prevent
502934702,7/14/2014 17:01:37,,1322964052,7/14/2014 17:01:31,neodev,0.875,17610000,GBR,I2,Manchester,90.200.140.201,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS causes TARDIVE DYSKINESIA,51,0,,96,18,causes,0.99654575824488,903749-FS1-4,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA,RO-has_causative_agent
502934702,7/14/2014 17:08:38,,1322967359,7/14/2014 17:08:32,neodev,0.6389,25224036,CAN,ON,Sudbury,67.204.218.187,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS causes TARDIVE DYSKINESIA,51,0,,96,18,causes,0.99654575824488,903749-FS1-4,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA,RO-has_causative_agent
502934702,7/14/2014 17:13:01,,1322969728,7/14/2014 17:12:38,instagc,0.5208,19636746,USA,NY,Andover,192.182.216.225,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS causes TARDIVE DYSKINESIA,51,0,,96,18,causes,0.99654575824488,903749-FS1-4,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA,RO-has_causative_agent
502934702,7/14/2014 17:27:21,,1322977560,7/14/2014 17:27:08,pokerowned,0.5639,18747884,USA,MI,Snover,209.40.219.170,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS causes TARDIVE DYSKINESIA,51,0,,96,18,causes,0.99654575824488,903749-FS1-4,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA,RO-has_causative_agent
502934702,7/14/2014 17:51:19,,1322997293,7/14/2014 17:50:59,clixsense,0.6389,19803139,NLD,06,Veldhoven,212.61.84.196,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS causes TARDIVE DYSKINESIA,51,0,,96,18,causes,0.99654575824488,903749-FS1-4,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA,RO-has_causative_agent
502934702,7/14/2014 18:03:20,,1323002686,7/14/2014 18:03:07,prodege,0.4264,12944140,GBR,I4,Mitcham,92.21.55.247,no_relation,51,0,,96,18,causes,0.99654575824488,903749-FS1-4,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA,RO-has_causative_agent
502934702,7/14/2014 18:08:46,,1323006556,7/14/2014 18:08:18,vivatic,0.605,25451531,GBR,"","",83.67.28.193,TARDIVE DYSKINESIA causes LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,51,0,,96,18,causes,0.99654575824488,903749-FS1-4,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA,RO-has_causative_agent
502934703,7/14/2014 17:01:08,,1322963745,7/14/2014 17:01:03,neodev,0.875,17610000,GBR,I2,Manchester,90.200.140.201,HYPERTENSION causes WILMS' TUMOR,0,68,,11,80,causes,0.970494958830946,902898-FS1-4,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR,RO-disease_may_have_finding
502934703,7/14/2014 17:01:32,,1322964004,7/14/2014 17:01:12,clixsense,0.8194,27793793,GBR,C5,Chester,151.230.27.155,WILMS' TUMOR causes HYPERTENSION,0,68,,11,80,causes,0.970494958830946,902898-FS1-4,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR,RO-disease_may_have_finding
502934703,7/14/2014 17:08:25,,1322967228,7/14/2014 17:08:20,neodev,0.6389,25224036,CAN,ON,Sudbury,67.204.218.187,HYPERTENSION causes WILMS' TUMOR,0,68,,11,80,causes,0.970494958830946,902898-FS1-4,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR,RO-disease_may_have_finding
502934703,7/14/2014 17:26:52,,1322977181,7/14/2014 17:26:41,pokerowned,0.5639,18747884,USA,MI,Snover,209.40.219.170,HYPERTENSION causes WILMS' TUMOR,0,68,,11,80,causes,0.970494958830946,902898-FS1-4,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR,RO-disease_may_have_finding
502934703,7/14/2014 18:03:05,,1323002592,7/14/2014 18:02:59,prodege,0.4264,12944140,GBR,I4,Mitcham,92.21.55.247,no_relation,0,68,,11,80,causes,0.970494958830946,902898-FS1-4,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR,RO-disease_may_have_finding
502934703,7/14/2014 18:07:57,,1323006138,7/14/2014 18:07:31,instagc,0.4639,28519532,USA,IA,Honey Creek,12.73.110.131,no_relation,0,68,,11,80,causes,0.970494958830946,902898-FS1-4,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR,RO-disease_may_have_finding
502934703,7/14/2014 18:08:17,,1323006335,7/14/2014 18:07:42,vivatic,0.605,25451531,GBR,"","",83.67.28.193,no_relation,0,68,,11,80,causes,0.970494958830946,902898-FS1-4,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR,RO-disease_may_have_finding
502934704,7/14/2014 17:23:48,,1322975120,7/14/2014 17:23:33,instagc,0.8125,18960682,GBR,"","",86.29.147.112,OCA2 causes SKIN AND HAIR PIGMENTATION,122,29,,147,33,causes,0.316227766016838,905331-FS1-4,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2,RO-has_finding_site
502934704,7/14/2014 17:30:29,,1322980104,7/14/2014 17:29:50,elite,0.5833,28276268,USA,MI,Taylor,67.149.247.166,OCA2 causes SKIN AND HAIR PIGMENTATION,122,29,,147,33,causes,0.316227766016838,905331-FS1-4,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2,RO-has_finding_site
502934704,7/14/2014 17:58:39,,1323000663,7/14/2014 17:58:04,neodev,0.6641,28269997,GBR,H9,London,151.224.171.48,OCA2 causes SKIN AND HAIR PIGMENTATION,122,29,,147,33,causes,0.316227766016838,905331-FS1-4,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2,RO-has_finding_site
502934704,7/14/2014 18:02:58,,1323002567,7/14/2014 18:02:46,prodege,0.4264,12944140,GBR,I4,Mitcham,92.21.55.247,no_relation,122,29,,147,33,causes,0.316227766016838,905331-FS1-4,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2,RO-has_finding_site
502934704,7/14/2014 18:08:17,,1323006334,7/14/2014 18:07:42,vivatic,0.605,25451531,GBR,"","",83.67.28.193,OCA2 causes SKIN AND HAIR PIGMENTATION,122,29,,147,33,causes,0.316227766016838,905331-FS1-4,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2,RO-has_finding_site
502934704,7/14/2014 18:28:54,,1323015407,7/14/2014 18:28:34,neodev,0.6095,21515166,NLD,11,Nootdorp,83.86.58.179,OCA2 causes SKIN AND HAIR PIGMENTATION,122,29,,147,33,causes,0.316227766016838,905331-FS1-4,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2,RO-has_finding_site
502934704,7/14/2014 18:47:10,,1323023817,7/14/2014 18:47:04,clixsense,0.4121,19162475,GBR,M3,Frome,82.33.126.30,SKIN AND HAIR PIGMENTATION causes OCA2,122,29,,147,33,causes,0.316227766016838,905331-FS1-4,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2,RO-has_finding_site
502934705,7/14/2014 17:01:14,,1322963812,7/14/2014 17:01:09,neodev,0.875,17610000,GBR,I2,Manchester,90.200.140.201,BRONCHIAL HYPERREACTIVITY treats SINGLE METHACHOLINE STIMULATION,201,133,,225,164,treats,0.324442842261525,906678-FS1-2,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION,RO-may_diagnose
502934705,7/14/2014 17:23:32,,1322974920,7/14/2014 17:23:22,instagc,0.8125,18960682,GBR,"","",86.29.147.112,no_relation,201,133,,225,164,treats,0.324442842261525,906678-FS1-2,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION,RO-may_diagnose
502934705,7/14/2014 17:58:03,,1323000451,7/14/2014 17:56:59,neodev,0.6641,28269997,GBR,H9,London,151.224.171.48,no_relation,201,133,,225,164,treats,0.324442842261525,906678-FS1-2,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION,RO-may_diagnose
502934705,7/14/2014 18:07:54,,1323006122,7/14/2014 18:06:59,prodege,0.5502,7899370,USA,MI,Bay City,71.13.81.162,SINGLE METHACHOLINE STIMULATION treats BRONCHIAL HYPERREACTIVITY,201,133,,225,164,treats,0.324442842261525,906678-FS1-2,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION,RO-may_diagnose
502934705,7/14/2014 18:32:49,,1323017090,7/14/2014 18:32:30,clixsense,0.7071,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,201,133,,225,164,treats,0.324442842261525,906678-FS1-2,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION,RO-may_diagnose
502934705,7/14/2014 19:29:58,,1323049399,7/14/2014 19:29:21,neodev,0.6472,14861092,GBR,I2,Manchester,90.194.137.76,SINGLE METHACHOLINE STIMULATION treats BRONCHIAL HYPERREACTIVITY,201,133,,225,164,treats,0.324442842261525,906678-FS1-2,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION,RO-may_diagnose
502934705,7/14/2014 19:30:13,,1323049613,7/14/2014 19:29:50,clixsense,0.3921,15189335,GBR,A7,Birmingham,94.197.121.232,SINGLE METHACHOLINE STIMULATION treats BRONCHIAL HYPERREACTIVITY,201,133,,225,164,treats,0.324442842261525,906678-FS1-2,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION,RO-may_diagnose
502934706,7/14/2014 16:59:26,,1322962732,7/14/2014 16:59:13,instagc,1.0,27753923,GBR,"","",94.196.229.196,BONE MARROW CELLS causes CHRONIC GRANULOCYTIC LEUKEMIA CELLS,67,13,,83,48,causes,0.3,902419-FS1-4,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS,RO-disease_has_primary_anatomic_site
502934706,7/14/2014 17:10:50,,1322968598,7/14/2014 17:10:29,instagc,0.5208,19636746,USA,NY,Andover,192.182.216.225,no_relation,67,13,,83,48,causes,0.3,902419-FS1-4,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS,RO-disease_has_primary_anatomic_site
502934706,7/14/2014 17:23:32,,1322974913,7/14/2014 17:23:22,instagc,0.8125,18960682,GBR,"","",86.29.147.112,no_relation,67,13,,83,48,causes,0.3,902419-FS1-4,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS,RO-disease_has_primary_anatomic_site
502934706,7/14/2014 17:26:40,,1322977025,7/14/2014 17:26:26,pokerowned,0.5639,18747884,USA,MI,Snover,209.40.219.170,BONE MARROW CELLS causes CHRONIC GRANULOCYTIC LEUKEMIA CELLS,67,13,,83,48,causes,0.3,902419-FS1-4,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS,RO-disease_has_primary_anatomic_site
502934706,7/14/2014 17:50:14,,1322996739,7/14/2014 17:50:07,prodege,0.6667,2143114,CAN,BC,Vancouver,24.84.160.12,CHRONIC GRANULOCYTIC LEUKEMIA CELLS causes BONE MARROW CELLS,67,13,,83,48,causes,0.3,902419-FS1-4,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS,RO-disease_has_primary_anatomic_site
502934706,7/14/2014 18:10:16,,1323007275,7/14/2014 18:09:58,prodege,0.5502,7899370,USA,MI,Bay City,71.13.81.162,no_relation,67,13,,83,48,causes,0.3,902419-FS1-4,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS,RO-disease_has_primary_anatomic_site
502934706,7/14/2014 19:30:53,,1323049975,7/14/2014 19:30:31,clixsense,0.3921,15189335,GBR,A7,Birmingham,94.197.121.232,no_relation,67,13,,83,48,causes,0.3,902419-FS1-4,"By contrast, CHRONIC GRANULOCYTIC LEUKEMIA CELLS as well as normal BONE MARROW CELLS lymphocytes, and monocytes, contain predominantly low molecular weight (less than 95 kDa) tyrosine kinase substrates.",BONE MARROW CELLS,CHRONIC GRANULOCYTIC LEUKEMIA CELLS,RO-disease_has_primary_anatomic_site
502934707,7/14/2014 16:59:26,,1322962731,7/14/2014 16:59:13,instagc,1.0,27753923,GBR,"","",94.196.229.196,ACETABULAR DYSPLASIA causes DEVELOPMENTAL DYSPLASIA OF THE HIP,55,10,,88,30,causes,0.693375245281537,906484-FS1-4,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA,RO-has_manifestation
502934707,7/14/2014 17:01:48,,1322964155,7/14/2014 17:01:33,clixsense,0.8194,27793793,GBR,C5,Chester,151.230.27.155,no_relation,55,10,,88,30,causes,0.693375245281537,906484-FS1-4,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA,RO-has_manifestation
502934707,7/14/2014 17:31:04,,1322980627,7/14/2014 17:30:30,elite,0.5833,28276268,USA,MI,Taylor,67.149.247.166,ACETABULAR DYSPLASIA causes DEVELOPMENTAL DYSPLASIA OF THE HIP,55,10,,88,30,causes,0.693375245281537,906484-FS1-4,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA,RO-has_manifestation
502934707,7/14/2014 17:50:14,,1322996738,7/14/2014 17:50:07,prodege,0.6667,2143114,CAN,BC,Vancouver,24.84.160.12,ACETABULAR DYSPLASIA causes DEVELOPMENTAL DYSPLASIA OF THE HIP,55,10,,88,30,causes,0.693375245281537,906484-FS1-4,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA,RO-has_manifestation
502934707,7/14/2014 18:07:25,,1323005931,7/14/2014 18:06:33,instagc,0.4639,28519532,USA,IA,Honey Creek,12.73.110.131,DEVELOPMENTAL DYSPLASIA OF THE HIP causes ACETABULAR DYSPLASIA,55,10,,88,30,causes,0.693375245281537,906484-FS1-4,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA,RO-has_manifestation
502934707,7/14/2014 18:09:42,,1323007003,7/14/2014 18:08:47,vivatic,0.605,25451531,GBR,"","",83.67.28.193,no_relation,55,10,,88,30,causes,0.693375245281537,906484-FS1-4,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA,RO-has_manifestation
502934707,7/14/2014 19:14:04,,1323039640,7/14/2014 19:13:40,elite,0.6234,28503042,USA,NJ,Woodbridge,54.191.150.115,DEVELOPMENTAL DYSPLASIA OF THE HIP causes ACETABULAR DYSPLASIA,55,10,,88,30,causes,0.693375245281537,906484-FS1-4,Untreated ACETABULAR DYSPLASIA following treatment for DEVELOPMENTAL DYSPLASIA OF THE HIP (DDH) leads to early degenerative joint disease.,DEVELOPMENTAL DYSPLASIA OF THE HIP,ACETABULAR DYSPLASIA,RO-has_manifestation
502934708,7/14/2014 16:59:11,,1322962638,7/14/2014 16:59:07,instagc,1.0,27753923,GBR,"","",94.196.229.196,END STAGE RENAL DISEASE causes RENAL OSTEODYSTROPHY,0,76,,19,99,causes,0.964901281354015,900397-FS1-4,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE,RO-cause_of
502934708,7/14/2014 17:01:02,,1322963647,7/14/2014 17:00:56,neodev,0.875,17610000,GBR,I2,Manchester,90.200.140.201,RENAL OSTEODYSTROPHY causes END STAGE RENAL DISEASE,0,76,,19,99,causes,0.964901281354015,900397-FS1-4,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE,RO-cause_of
502934708,7/14/2014 18:08:39,,1323006509,7/14/2014 18:08:01,instagc,0.4639,28519532,USA,IA,Honey Creek,12.73.110.131,no_relation,0,76,,19,99,causes,0.964901281354015,900397-FS1-4,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE,RO-cause_of
502934708,7/14/2014 19:18:27,,1323042301,7/14/2014 19:17:58,instagc,0.7278,13763729,USA,"","",75.182.89.225,no_relation,0,76,,19,99,causes,0.964901281354015,900397-FS1-4,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE,RO-cause_of
502934708,7/14/2014 19:29:48,,1323049331,7/14/2014 19:29:22,clixsense,0.3921,15189335,GBR,A7,Birmingham,94.197.121.232,RENAL OSTEODYSTROPHY causes END STAGE RENAL DISEASE,0,76,,19,99,causes,0.964901281354015,900397-FS1-4,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE,RO-cause_of
502934708,7/14/2014 19:32:39,,1323051264,7/14/2014 19:32:17,eup_slw,0.5952,20818028,GBR,A7,Birmingham,92.232.139.254,END STAGE RENAL DISEASE causes RENAL OSTEODYSTROPHY,0,76,,19,99,causes,0.964901281354015,900397-FS1-4,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE,RO-cause_of
502934708,7/14/2014 19:33:07,,1323051503,7/14/2014 19:32:40,neodev,0.7222,21752395,USA,"","",173.23.121.63,END STAGE RENAL DISEASE causes RENAL OSTEODYSTROPHY,0,76,,19,99,causes,0.964901281354015,900397-FS1-4,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE,RO-cause_of
502934709,7/14/2014 16:59:39,,1322962844,7/14/2014 16:59:28,instagc,1.0,27753923,GBR,"","",94.196.229.196,ALLERGY causes HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,76,20,,118,27,causes,0.919145030018058,900033-FS1-4,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY,RO-cause_of
502934709,7/14/2014 17:30:29,,1322980100,7/14/2014 17:29:50,elite,0.5833,28276268,USA,MI,Taylor,67.149.247.166,ALLERGY causes HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,76,20,,118,27,causes,0.919145030018058,900033-FS1-4,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY,RO-cause_of
502934709,7/14/2014 18:02:45,,1323002451,7/14/2014 18:02:17,prodege,0.4264,12944140,GBR,I4,Mitcham,92.21.55.247,no_relation,76,20,,118,27,causes,0.919145030018058,900033-FS1-4,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY,RO-cause_of
502934709,7/14/2014 18:09:57,,1323007104,7/14/2014 18:09:12,prodege,0.5502,7899370,USA,MI,Bay City,71.13.81.162,no_relation,76,20,,118,27,causes,0.919145030018058,900033-FS1-4,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY,RO-cause_of
502934709,7/14/2014 18:58:01,,1323030196,7/14/2014 18:57:06,instagc,0.5877,19686223,CAN,BC,Surrey,184.65.16.6,no_relation,76,20,,118,27,causes,0.919145030018058,900033-FS1-4,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY,RO-cause_of
502934709,7/14/2014 19:15:30,,1323040428,7/14/2014 19:15:12,elite,0.6234,28503042,USA,NJ,Woodbridge,54.191.150.115,ALLERGY causes HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,76,20,,118,27,causes,0.919145030018058,900033-FS1-4,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY,RO-cause_of
502934709,7/14/2014 19:33:55,,1323052009,7/14/2014 19:33:28,eup_slw,0.5952,20818028,GBR,A7,Birmingham,92.232.139.254,ALLERGY causes HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,76,20,,118,27,causes,0.919145030018058,900033-FS1-4,It is accepted that ALLERGY is not the sole cause of asthma but nonetheless HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS is a significant triggering factor in most countries of the world.,HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS,ALLERGY,RO-cause_of
502934710,7/14/2014 17:22:48,,1322974431,7/14/2014 17:22:38,instagc,0.8125,18960682,GBR,"","",86.29.147.112,no_relation,180,132,,189,147,causes,0.5,902584-FS1-4,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS,RO-disease_may_have_finding
502934710,7/14/2014 17:26:52,,1322977178,7/14/2014 17:26:41,pokerowned,0.5639,18747884,USA,MI,Snover,209.40.219.170,MULTIPLE POLYPS causes POLYP MASS,180,132,,189,147,causes,0.5,902584-FS1-4,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS,RO-disease_may_have_finding
502934710,7/14/2014 18:08:21,,1323006358,7/14/2014 18:07:56,prodege,0.5502,7899370,USA,MI,Bay City,71.13.81.162,no_relation,180,132,,189,147,causes,0.5,902584-FS1-4,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS,RO-disease_may_have_finding
502934710,7/14/2014 18:09:13,,1323006801,7/14/2014 18:08:44,instagc,0.4639,28519532,USA,IA,Honey Creek,12.73.110.131,no_relation,180,132,,189,147,causes,0.5,902584-FS1-4,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS,RO-disease_may_have_finding
502934710,7/14/2014 18:33:40,,1323017391,7/14/2014 18:33:24,clixsense,0.7071,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,180,132,,189,147,causes,0.5,902584-FS1-4,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS,RO-disease_may_have_finding
502934710,7/14/2014 18:59:38,,1323031309,7/14/2014 18:59:04,instagc,0.5877,19686223,CAN,BC,Surrey,184.65.16.6,no_relation,180,132,,189,147,causes,0.5,902584-FS1-4,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS,RO-disease_may_have_finding
502934710,7/14/2014 19:20:21,,1323043516,7/14/2014 19:19:24,instagc,0.7278,13763729,USA,"","",75.182.89.225,no_relation,180,132,,189,147,causes,0.5,902584-FS1-4,"We have established a pre operative diagnosis in four cases of non secretory gastric carcinoid of the body and fundus presenting as MULTIPLE POLYPS in three patients, and a single POLYP MASS in the fourth patient.",POLYP MASS,MULTIPLE POLYPS,RO-disease_may_have_finding
502934711,7/14/2014 17:01:21,,1322963902,7/14/2014 17:01:15,neodev,0.875,17610000,GBR,I2,Manchester,90.200.140.201,JOINTS causes ARTHRITIS,27,0,,32,9,causes,0.433012701892219,902293-FS1-4,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502934711,7/14/2014 17:08:18,,1322967170,7/14/2014 17:07:23,neodev,0.6389,25224036,CAN,ON,Sudbury,67.204.218.187,ARTHRITIS causes JOINTS,27,0,,32,9,causes,0.433012701892219,902293-FS1-4,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502934711,7/14/2014 17:12:36,,1322969568,7/14/2014 17:12:22,instagc,0.5208,19636746,USA,NY,Andover,192.182.216.225,no_relation,27,0,,32,9,causes,0.433012701892219,902293-FS1-4,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502934711,7/14/2014 17:27:38,,1322977749,7/14/2014 17:27:21,pokerowned,0.5639,18747884,USA,MI,Snover,209.40.219.170,no_relation,27,0,,32,9,causes,0.433012701892219,902293-FS1-4,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502934711,7/14/2014 17:31:04,,1322980624,7/14/2014 17:30:30,elite,0.5833,28276268,USA,MI,Taylor,67.149.247.166,ARTHRITIS causes JOINTS,27,0,,32,9,causes,0.433012701892219,902293-FS1-4,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502934711,7/14/2014 18:28:54,,1323015406,7/14/2014 18:28:34,neodev,0.6095,21515166,NLD,11,Nootdorp,83.86.58.179,ARTHRITIS causes JOINTS,27,0,,32,9,causes,0.433012701892219,902293-FS1-4,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502934711,7/14/2014 18:47:02,,1323023712,7/14/2014 18:46:54,clixsense,0.4121,19162475,GBR,M3,Frome,82.33.126.30,JOINTS causes ARTHRITIS,27,0,,32,9,causes,0.433012701892219,902293-FS1-4,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502934712,7/14/2014 17:11:45,,1322969093,7/14/2014 17:11:17,instagc,0.5208,19636746,USA,NY,Andover,192.182.216.225,no_relation,253,196,,268,219,causes,0.447213595499958,906130-FS1-4,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS,RO-has_manifestation
502934712,7/14/2014 17:49:22,,1322996402,7/14/2014 17:48:54,prodege,0.6667,2143114,CAN,BC,Vancouver,24.84.160.12,CRANIOFACIAL DYSOSTOSIS causes DIVERGENT SQUINT,253,196,,268,219,causes,0.447213595499958,906130-FS1-4,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS,RO-has_manifestation
502934712,7/14/2014 17:58:03,,1323000452,7/14/2014 17:56:59,neodev,0.6641,28269997,GBR,H9,London,151.224.171.48,no_relation,253,196,,268,219,causes,0.447213595499958,906130-FS1-4,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS,RO-has_manifestation
502934712,7/14/2014 18:46:23,,1323023343,7/14/2014 18:46:14,clixsense,0.4121,19162475,GBR,M3,Frome,82.33.126.30,DIVERGENT SQUINT causes CRANIOFACIAL DYSOSTOSIS,253,196,,268,219,causes,0.447213595499958,906130-FS1-4,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS,RO-has_manifestation
502934712,7/14/2014 18:57:05,,1323029463,7/14/2014 18:56:38,instagc,0.5877,19686223,CAN,BC,Surrey,184.65.16.6,no_relation,253,196,,268,219,causes,0.447213595499958,906130-FS1-4,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS,RO-has_manifestation
502934712,7/14/2014 19:13:38,,1323039436,7/14/2014 19:13:12,elite,0.6234,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,253,196,,268,219,causes,0.447213595499958,906130-FS1-4,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS,RO-has_manifestation
502934712,7/14/2014 19:31:01,,1323050046,7/14/2014 19:30:45,neodev,0.6472,14861092,GBR,I2,Manchester,90.194.137.76,no_relation,253,196,,268,219,causes,0.447213595499958,906130-FS1-4,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS,RO-has_manifestation
502934713,7/14/2014 17:29:09,,1322978940,7/14/2014 17:28:15,elite,0.5833,28276268,USA,MI,Taylor,67.149.247.166,INHERITED RICKETS treats VITAMIN D,143,188,,159,197,treats,0.685994340570035,908221-FS1-2,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D,RO-may_treat
502934713,7/14/2014 17:59:59,,1323001191,7/14/2014 17:59:27,neodev,0.6641,28269997,GBR,H9,London,151.224.171.48,VITAMIN D treats INHERITED RICKETS,143,188,,159,197,treats,0.685994340570035,908221-FS1-2,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D,RO-may_treat
502934713,7/14/2014 18:06:59,,1323005729,7/14/2014 18:05:53,prodege,0.5502,7899370,USA,MI,Bay City,71.13.81.162,VITAMIN D treats INHERITED RICKETS,143,188,,159,197,treats,0.685994340570035,908221-FS1-2,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D,RO-may_treat
502934713,7/14/2014 18:29:32,,1323015622,7/14/2014 18:29:18,instagc,0.6187,28524232,CAN,ON,Toronto,99.244.116.246,VITAMIN D treats INHERITED RICKETS,143,188,,159,197,treats,0.685994340570035,908221-FS1-2,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D,RO-may_treat
502934713,7/14/2014 18:50:12,,1323025379,7/14/2014 18:49:50,instagc,0.5869,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,143,188,,159,197,treats,0.685994340570035,908221-FS1-2,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D,RO-may_treat
502934713,7/14/2014 19:14:41,,1323040017,7/14/2014 19:14:06,elite,0.6234,28503042,USA,NJ,Woodbridge,54.191.150.115,VITAMIN D treats INHERITED RICKETS,143,188,,159,197,treats,0.685994340570035,908221-FS1-2,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D,RO-may_treat
502934713,7/14/2014 19:17:32,,1323041675,7/14/2014 19:17:06,instagc,0.7278,13763729,USA,"","",75.182.89.225,VITAMIN D treats INHERITED RICKETS,143,188,,159,197,treats,0.685994340570035,908221-FS1-2,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D,RO-may_treat
502934714,7/14/2014 16:59:06,,1322962611,7/14/2014 16:59:01,instagc,1.0,27753923,GBR,"","",94.196.229.196,NICOTINE AND COTININE LEVELS causes NICOTINE DEPENDENCE,184,160,,211,179,causes,0.424264068711929,903879-FS1-4,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE,RO-has_causative_agent
502934714,7/14/2014 17:00:31,,1322963239,7/14/2014 16:59:44,clixsense,0.8611,27871219,NLD,07,Amsterdam,87.210.207.223,NICOTINE AND COTININE LEVELS causes NICOTINE DEPENDENCE,184,160,,211,179,causes,0.424264068711929,903879-FS1-4,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE,RO-has_causative_agent
502934714,7/14/2014 17:29:49,,1322979547,7/14/2014 17:29:11,elite,0.5833,28276268,USA,MI,Taylor,67.149.247.166,NICOTINE DEPENDENCE causes NICOTINE AND COTININE LEVELS,184,160,,211,179,causes,0.424264068711929,903879-FS1-4,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE,RO-has_causative_agent
502934714,7/14/2014 17:49:43,,1322996556,7/14/2014 17:49:34,prodege,0.6667,2143114,CAN,BC,Vancouver,24.84.160.12,NICOTINE AND COTININE LEVELS causes NICOTINE DEPENDENCE,184,160,,211,179,causes,0.424264068711929,903879-FS1-4,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE,RO-has_causative_agent
502934714,7/14/2014 18:08:39,,1323006520,7/14/2014 18:08:01,instagc,0.4639,28519532,USA,IA,Honey Creek,12.73.110.131,no_relation,184,160,,211,179,causes,0.424264068711929,903879-FS1-4,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE,RO-has_causative_agent
502934714,7/14/2014 18:29:32,,1323015621,7/14/2014 18:29:18,instagc,0.6187,28524232,CAN,ON,Toronto,99.244.116.246,no_relation,184,160,,211,179,causes,0.424264068711929,903879-FS1-4,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE,RO-has_causative_agent
502934714,7/14/2014 18:47:02,,1323023690,7/14/2014 18:46:54,clixsense,0.4121,19162475,GBR,M3,Frome,82.33.126.30,NICOTINE AND COTININE LEVELS causes NICOTINE DEPENDENCE,184,160,,211,179,causes,0.424264068711929,903879-FS1-4,"The objective of the present study was to investigate the interaction between a variation in the 5 HTTLPR and family environment in relation to smoking habits, NICOTINE DEPENDENCE and NICOTINE AND COTININE LEVELS in hair samples.",NICOTINE AND COTININE LEVELS,NICOTINE DEPENDENCE,RO-has_causative_agent
502934715,7/14/2014 16:59:06,,1322962608,7/14/2014 16:59:01,instagc,1.0,27753923,GBR,"","",94.196.229.196,DRUG SIDE EFFECTS causes DRUG REGIMENS,240,267,,252,284,causes,0.833333333333333,903825-FS1-4,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS,RO-has_causative_agent
502934715,7/14/2014 17:01:30,,1322963994,7/14/2014 17:01:22,neodev,0.875,17610000,GBR,I2,Manchester,90.200.140.201,DRUG REGIMENS causes DRUG SIDE EFFECTS,240,267,,252,284,causes,0.833333333333333,903825-FS1-4,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS,RO-has_causative_agent
502934715,7/14/2014 17:13:01,,1322969727,7/14/2014 17:12:38,instagc,0.5208,19636746,USA,NY,Andover,192.182.216.225,no_relation,240,267,,252,284,causes,0.833333333333333,903825-FS1-4,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS,RO-has_causative_agent
502934715,7/14/2014 17:27:28,,1322977645,7/14/2014 17:27:10,elite,0.5833,28276268,USA,MI,Taylor,67.149.247.166,DRUG REGIMENS causes DRUG SIDE EFFECTS,240,267,,252,284,causes,0.833333333333333,903825-FS1-4,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS,RO-has_causative_agent
502934715,7/14/2014 18:07:41,,1323006027,7/14/2014 18:06:56,vivatic,0.605,25451531,GBR,"","",83.67.28.193,DRUG REGIMENS causes DRUG SIDE EFFECTS,240,267,,252,284,causes,0.833333333333333,903825-FS1-4,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS,RO-has_causative_agent
502934715,7/14/2014 18:09:57,,1323007105,7/14/2014 18:09:12,prodege,0.5502,7899370,USA,MI,Bay City,71.13.81.162,no_relation,240,267,,252,284,causes,0.833333333333333,903825-FS1-4,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS,RO-has_causative_agent
502934715,7/14/2014 18:59:38,,1323031338,7/14/2014 18:59:04,instagc,0.5877,19686223,CAN,BC,Surrey,184.65.16.6,no_relation,240,267,,252,284,causes,0.833333333333333,903825-FS1-4,"This paper presents the results of a survey of the hypertensive patient population in a university family medicine practice to determine health beliefs, patient perceptions of the severity of their condition, stated levels of compliance to DRUG REGIMENS frequency of DRUG SIDE EFFECTS and frequency of physician discussions of drug side effects and diet.",DRUG REGIMENS,DRUG SIDE EFFECTS,RO-has_causative_agent
502934716,7/14/2014 17:08:18,,1322967169,7/14/2014 17:07:23,neodev,0.6389,25224036,CAN,ON,Sudbury,67.204.218.187,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,83,35,,102,48,treats,0.98058067569092,907754-FS1-2,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE,RO-may_treat
502934716,7/14/2014 17:10:50,,1322968584,7/14/2014 17:10:29,instagc,0.5208,19636746,USA,NY,Andover,192.182.216.225,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,83,35,,102,48,treats,0.98058067569092,907754-FS1-2,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE,RO-may_treat
502934716,7/14/2014 17:50:31,,1322996903,7/14/2014 17:50:12,clixsense,0.6389,19803139,NLD,06,Veldhoven,212.61.84.196,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,83,35,,102,48,treats,0.98058067569092,907754-FS1-2,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE,RO-may_treat
502934716,7/14/2014 18:29:18,,1323015542,7/14/2014 18:28:56,instagc,0.6187,28524232,CAN,ON,Toronto,99.244.116.246,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,83,35,,102,48,treats,0.98058067569092,907754-FS1-2,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE,RO-may_treat
502934716,7/14/2014 18:49:21,,1323024917,7/14/2014 18:49:09,instagc,0.5869,25990856,USA,NV,Las Vegas,68.108.98.78,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,83,35,,102,48,treats,0.98058067569092,907754-FS1-2,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE,RO-may_treat
502934716,7/14/2014 19:32:08,,1323050962,7/14/2014 19:31:23,clixsense,0.3921,15189335,GBR,A7,Birmingham,94.197.121.232,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,83,35,,102,48,treats,0.98058067569092,907754-FS1-2,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE,RO-may_treat
502934716,7/14/2014 19:32:39,,1323051250,7/14/2014 19:31:35,neodev,0.7222,21752395,USA,"","",173.23.121.63,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,83,35,,102,48,treats,0.98058067569092,907754-FS1-2,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE,RO-may_treat
502934717,7/14/2014 17:50:05,,1322996690,7/14/2014 17:49:57,prodege,0.6667,2143114,CAN,BC,Vancouver,24.84.160.12,INTRAVENOUS DANTROLENE causes MALIGNANT HYPERTHERMIA,39,87,,60,109,causes,0.371390676354104,908181-FS1-4,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934717,7/14/2014 18:00:33,,1323001463,7/14/2014 18:00:00,neodev,0.6641,28269997,GBR,H9,London,151.224.171.48,MALIGNANT HYPERTHERMIA causes INTRAVENOUS DANTROLENE,39,87,,60,109,causes,0.371390676354104,908181-FS1-4,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934717,7/14/2014 18:03:05,,1323002591,7/14/2014 18:02:59,prodege,0.4264,12944140,GBR,I4,Mitcham,92.21.55.247,no_relation,39,87,,60,109,causes,0.371390676354104,908181-FS1-4,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934717,7/14/2014 18:09:13,,1323006803,7/14/2014 18:08:44,instagc,0.4639,28519532,USA,IA,Honey Creek,12.73.110.131,no_relation,39,87,,60,109,causes,0.371390676354104,908181-FS1-4,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934717,7/14/2014 18:28:33,,1323015273,7/14/2014 18:28:13,neodev,0.6095,21515166,NLD,11,Nootdorp,83.86.58.179,INTRAVENOUS DANTROLENE causes MALIGNANT HYPERTHERMIA,39,87,,60,109,causes,0.371390676354104,908181-FS1-4,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934717,7/14/2014 18:56:37,,1323029097,7/14/2014 18:55:57,instagc,0.5877,19686223,CAN,BC,Surrey,184.65.16.6,MALIGNANT HYPERTHERMIA causes INTRAVENOUS DANTROLENE,39,87,,60,109,causes,0.371390676354104,908181-FS1-4,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934717,7/14/2014 19:13:10,,1323039171,7/14/2014 19:12:40,elite,0.6234,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,39,87,,60,109,causes,0.371390676354104,908181-FS1-4,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934718,7/14/2014 18:27:37,,1323014796,7/14/2014 18:27:17,neodev,0.6095,21515166,NLD,11,Nootdorp,83.86.58.179,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA treats RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,0,59,,39,108,treats,0.961523947640823,902788-FS1-2,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,RO-disease_may_have_finding
502934718,7/14/2014 18:33:07,,1323017194,7/14/2014 18:32:50,clixsense,0.7071,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,0,59,,39,108,treats,0.961523947640823,902788-FS1-2,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,RO-disease_may_have_finding
502934718,7/14/2014 18:50:12,,1323025377,7/14/2014 18:49:50,instagc,0.5869,25990856,USA,NV,Las Vegas,68.108.98.78,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,0,59,,39,108,treats,0.961523947640823,902788-FS1-2,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,RO-disease_may_have_finding
502934718,7/14/2014 19:13:10,,1323039173,7/14/2014 19:12:40,elite,0.6234,28503042,USA,NJ,Woodbridge,54.191.150.115,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,0,59,,39,108,treats,0.961523947640823,902788-FS1-2,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,RO-disease_may_have_finding
502934718,7/14/2014 19:31:21,,1323050445,7/14/2014 19:30:54,clixsense,0.3921,15189335,GBR,A7,Birmingham,94.197.121.232,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,0,59,,39,108,treats,0.961523947640823,902788-FS1-2,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,RO-disease_may_have_finding
502934718,7/14/2014 19:31:34,,1323050585,7/14/2014 19:30:53,neodev,0.7222,21752395,USA,"","",173.23.121.63,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,0,59,,39,108,treats,0.961523947640823,902788-FS1-2,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,RO-disease_may_have_finding
502934718,7/14/2014 19:33:03,,1323051475,7/14/2014 19:32:40,eup_slw,0.5952,20818028,GBR,A7,Birmingham,92.232.139.254,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA treats PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,0,59,,39,108,treats,0.961523947640823,902788-FS1-2,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA has been used for PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA under ultrasound guidance in local anesthesia.,RADIOFREQUENCY INTERSTITIAL HYPERTHERMIA,PERCUTANEOUS ABLATION OF HEPATOCELLULAR CARCINOMA,RO-disease_may_have_finding
502934719,7/14/2014 16:59:00,,1322962574,7/14/2014 16:58:55,instagc,1.0,27753923,GBR,"","",94.196.229.196,FLUCTUATING PARKINSON'S DISEASE treats LEVODOPA/DDCI,52,102,,82,115,treats,0.987878339907213,908084-FS1-2,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI,RO-may_treat
502934719,7/14/2014 17:11:45,,1322969094,7/14/2014 17:11:17,instagc,0.5208,19636746,USA,NY,Andover,192.182.216.225,LEVODOPA/DDCI treats FLUCTUATING PARKINSON'S DISEASE,52,102,,82,115,treats,0.987878339907213,908084-FS1-2,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI,RO-may_treat
502934719,7/14/2014 17:28:13,,1322978206,7/14/2014 17:27:31,elite,0.5833,28276268,USA,MI,Taylor,67.149.247.166,LEVODOPA/DDCI treats FLUCTUATING PARKINSON'S DISEASE,52,102,,82,115,treats,0.987878339907213,908084-FS1-2,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI,RO-may_treat
502934719,7/14/2014 17:49:56,,1322996620,7/14/2014 17:49:45,prodege,0.6667,2143114,CAN,BC,Vancouver,24.84.160.12,LEVODOPA/DDCI treats FLUCTUATING PARKINSON'S DISEASE,52,102,,82,115,treats,0.987878339907213,908084-FS1-2,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI,RO-may_treat
502934719,7/14/2014 18:09:47,,1323007062,7/14/2014 18:09:18,instagc,0.4639,28519532,USA,IA,Honey Creek,12.73.110.131,LEVODOPA/DDCI treats FLUCTUATING PARKINSON'S DISEASE,52,102,,82,115,treats,0.987878339907213,908084-FS1-2,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI,RO-may_treat
502934719,7/14/2014 18:22:39,,1323012801,7/14/2014 18:21:55,instagc,0.6187,28524232,CAN,ON,Toronto,99.244.116.246,no_relation,52,102,,82,115,treats,0.987878339907213,908084-FS1-2,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI,RO-may_treat
502934719,7/14/2014 18:27:37,,1323014793,7/14/2014 18:27:17,neodev,0.6095,21515166,NLD,11,Nootdorp,83.86.58.179,LEVODOPA/DDCI treats FLUCTUATING PARKINSON'S DISEASE,52,102,,82,115,treats,0.987878339907213,908084-FS1-2,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI,RO-may_treat
502934720,7/14/2014 17:01:14,,1322963823,7/14/2014 17:01:09,neodev,0.875,17610000,GBR,I2,Manchester,90.200.140.201,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA diagnosed by POLYCYTHAEMIA VERA,132,85,,173,103,diagnosed by,0.365148371670111,906409-FS1-13,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA,RO-has_manifestation
502934720,7/14/2014 17:01:32,,1322963999,7/14/2014 17:01:12,clixsense,0.8194,27793793,GBR,C5,Chester,151.230.27.155,no_relation,132,85,,173,103,diagnosed by,0.365148371670111,906409-FS1-13,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA,RO-has_manifestation
502934720,7/14/2014 17:01:55,,1322964193,7/14/2014 17:01:24,clixsense,0.8611,27871219,NLD,07,Amsterdam,87.210.207.223,no_relation,132,85,,173,103,diagnosed by,0.365148371670111,906409-FS1-13,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA,RO-has_manifestation
502934720,7/14/2014 17:22:36,,1322974314,7/14/2014 17:22:25,instagc,0.8125,18960682,GBR,"","",86.29.147.112,no_relation,132,85,,173,103,diagnosed by,0.365148371670111,906409-FS1-13,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA,RO-has_manifestation
502934720,7/14/2014 17:29:49,,1322979548,7/14/2014 17:29:11,elite,0.5833,28276268,USA,MI,Taylor,67.149.247.166,POLYCYTHAEMIA VERA diagnosed by THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,132,85,,173,103,diagnosed by,0.365148371670111,906409-FS1-13,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA,RO-has_manifestation
502934720,7/14/2014 17:50:57,,1322997097,7/14/2014 17:50:32,clixsense,0.6389,19803139,NLD,06,Veldhoven,212.61.84.196,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA diagnosed by POLYCYTHAEMIA VERA,132,85,,173,103,diagnosed by,0.365148371670111,906409-FS1-13,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA,RO-has_manifestation
502934720,7/14/2014 18:01:00,,1323001721,7/14/2014 18:00:33,neodev,0.6641,28269997,GBR,H9,London,151.224.171.48,no_relation,132,85,,173,103,diagnosed by,0.365148371670111,906409-FS1-13,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA,RO-has_manifestation
502934721,7/14/2014 16:59:46,,1322962878,7/14/2014 16:59:41,instagc,1.0,27753923,GBR,"","",94.196.229.196,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,39,87,,60,109,treats,0.557086014531156,908181-FS1-2,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934721,7/14/2014 17:02:21,,1322964373,7/14/2014 17:01:56,clixsense,0.8611,27871219,NLD,07,Amsterdam,87.210.207.223,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,39,87,,60,109,treats,0.557086014531156,908181-FS1-2,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934721,7/14/2014 17:59:26,,1323000981,7/14/2014 17:58:40,neodev,0.6641,28269997,GBR,H9,London,151.224.171.48,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,39,87,,60,109,treats,0.557086014531156,908181-FS1-2,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934721,7/14/2014 18:02:45,,1323002450,7/14/2014 18:02:17,prodege,0.4264,12944140,GBR,I4,Mitcham,92.21.55.247,no_relation,39,87,,60,109,treats,0.557086014531156,908181-FS1-2,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934721,7/14/2014 18:27:57,,1323014969,7/14/2014 18:27:38,neodev,0.6095,21515166,NLD,11,Nootdorp,83.86.58.179,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,39,87,,60,109,treats,0.557086014531156,908181-FS1-2,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934721,7/14/2014 18:30:41,,1323016172,7/14/2014 18:30:00,instagc,0.6187,28524232,CAN,ON,Toronto,99.244.116.246,INTRAVENOUS DANTROLENE treats MALIGNANT HYPERTHERMIA,39,87,,60,109,treats,0.557086014531156,908181-FS1-2,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934721,7/14/2014 18:49:41,,1323025097,7/14/2014 18:49:36,clixsense,0.4121,19162475,GBR,M3,Frome,82.33.126.30,MALIGNANT HYPERTHERMIA treats INTRAVENOUS DANTROLENE,39,87,,60,109,treats,0.557086014531156,908181-FS1-2,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934722,7/14/2014 17:00:52,,1322963556,7/14/2014 17:00:32,clixsense,0.8611,27871219,NLD,07,Amsterdam,87.210.207.223,MALIGNANT HYPERTHERMIA diagnosed by INTRAVENOUS DANTROLENE,39,87,,60,109,diagnosed by,0.742781352708207,908181-FS1-13,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934722,7/14/2014 17:08:54,,1322967521,7/14/2014 17:08:48,neodev,0.6389,25224036,CAN,ON,Sudbury,67.204.218.187,INTRAVENOUS DANTROLENE diagnosed by MALIGNANT HYPERTHERMIA,39,87,,60,109,diagnosed by,0.742781352708207,908181-FS1-13,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934722,7/14/2014 17:12:21,,1322969407,7/14/2014 17:11:45,instagc,0.5208,19636746,USA,NY,Andover,192.182.216.225,no_relation,39,87,,60,109,diagnosed by,0.742781352708207,908181-FS1-13,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934722,7/14/2014 17:27:07,,1322977444,7/14/2014 17:26:53,pokerowned,0.5639,18747884,USA,MI,Snover,209.40.219.170,MALIGNANT HYPERTHERMIA diagnosed by INTRAVENOUS DANTROLENE,39,87,,60,109,diagnosed by,0.742781352708207,908181-FS1-13,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934722,7/14/2014 17:49:32,,1322996463,7/14/2014 17:49:19,clixsense,0.6389,19803139,NLD,06,Veldhoven,212.61.84.196,INTRAVENOUS DANTROLENE diagnosed by MALIGNANT HYPERTHERMIA,39,87,,60,109,diagnosed by,0.742781352708207,908181-FS1-13,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934722,7/14/2014 17:49:43,,1322996555,7/14/2014 17:49:34,prodege,0.6667,2143114,CAN,BC,Vancouver,24.84.160.12,MALIGNANT HYPERTHERMIA diagnosed by INTRAVENOUS DANTROLENE,39,87,,60,109,diagnosed by,0.742781352708207,908181-FS1-13,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934722,7/14/2014 18:07:54,,1323006123,7/14/2014 18:06:59,prodege,0.5502,7899370,USA,MI,Bay City,71.13.81.162,no_relation,39,87,,60,109,diagnosed by,0.742781352708207,908181-FS1-13,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE,RO-may_treat
502934723,7/14/2014 18:00:33,,1323001464,7/14/2014 18:00:00,neodev,0.6641,28269997,GBR,H9,London,151.224.171.48,no_relation,123,228,,150,245,causes,0.794719414239026,902537-FS1-4,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA,RO-disease_may_have_finding
502934723,7/14/2014 18:30:00,,1323015833,7/14/2014 18:29:33,instagc,0.6187,28524232,CAN,ON,Toronto,99.244.116.246,no_relation,123,228,,150,245,causes,0.794719414239026,902537-FS1-4,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA,RO-disease_may_have_finding
502934723,7/14/2014 18:48:51,,1323024647,7/14/2014 18:48:32,instagc,0.5869,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,123,228,,150,245,causes,0.794719414239026,902537-FS1-4,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA,RO-disease_may_have_finding
502934723,7/14/2014 18:59:02,,1323030874,7/14/2014 18:58:03,instagc,0.5877,19686223,CAN,BC,Surrey,184.65.16.6,no_relation,123,228,,150,245,causes,0.794719414239026,902537-FS1-4,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA,RO-disease_may_have_finding
502934723,7/14/2014 19:15:10,,1323040249,7/14/2014 19:14:43,elite,0.6234,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,123,228,,150,245,causes,0.794719414239026,902537-FS1-4,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA,RO-disease_may_have_finding
502934723,7/14/2014 19:17:32,,1323041674,7/14/2014 19:17:06,instagc,0.7278,13763729,USA,"","",75.182.89.225,no_relation,123,228,,150,245,causes,0.794719414239026,902537-FS1-4,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA,RO-disease_may_have_finding
502934723,7/14/2014 19:30:13,,1323049611,7/14/2014 19:29:50,clixsense,0.3921,15189335,GBR,A7,Birmingham,94.197.121.232,OVARIAN CARCINOMA causes UNFAVORABLE CLINICAL OUTCOME,123,228,,150,245,causes,0.794719414239026,902537-FS1-4,These results showed that high LAPTM4B expression was associated with progression of ovarian carcinoma and correlated with UNFAVORABLE CLINICAL OUTCOME suggesting that LAPTM4B may be a clinically useful prognostic indicator for OVARIAN CARCINOMA,UNFAVORABLE CLINICAL OUTCOME,OVARIAN CARCINOMA,RO-disease_may_have_finding
